[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fV4NUiOgkx6KI7rmEH_HqXQa1ZOTcnsjUcq81qDRi5HE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University Medical Center Groningen",[4],611,false,144,31,421519,54,417,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Heart Failure",18,{"name":18,"count":19},"Breast Cancer",16,{"name":21,"count":22},"Melanoma",12,{"name":24,"count":22},"COPD",{"name":26,"count":27},"Esophageal Cancer",11,{"name":29,"count":30},"Critical Illness",10,{"name":32,"count":30},"Cancer",{"name":34,"count":30},"Asthma",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03199300","Investigating Cardiovascular Adverse Events Related to Cancer Treatment","2025-02-06","Anthracyclines",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03797196","RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","2025-06","low dose tacrolimus in combination with everolimus",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05463913","Lung Nodule Detection Using Ultra-long FOV PET\u002FCT","2025-06-01","18F-FDG",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06606808","Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease","2025-08","Risankizumab-800CW 4.5 mg",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05483400","Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors","2025-09","Tiragolumab and atezolizumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04706715","LAG3 PET Imaging in Advanced Solid Tumors","2025-11","Cemiplimab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05641428","Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R\u002FR LBCL","2025-12","ARI-0001",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05525338","Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels","2025-12-31","Alectinib",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT03938701","Fluorescence Imaging of IBD and RA Using Adalimumab-800CW","2026-03","Adalimumab-800CW",{"nctId":82,"briefTitle":83,"date":79,"intervention":84},"NCT04646187","De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease","Infliximab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,121,139,161,188,214,239,264,282,321,368,394,422,486,559,596,633,658,682,700,718,746,764,790,808,830,848,866,893,911,929,954,983,1005,1023,1041,1059,1081,1102,1127,1155,1173,1191,1214,1250,1276,1294,1312,1330,1348,1379,1397,1421,1439,1465,1494,1524,1565,1603,1636,1661,1679,1704,1728,1756,1781,1806,1824,1849,1873,1897,1931,1958,1976,1994,2012,2030,2054,2083,2101,2127,2150,2175,2200,2218,2243,2268,2286,2327,2355,2392,2410,2439,2457,2475,2493,2518,2543,2561,2586,2612,2630,2655,2681,2699,2725,2751,2769,2794,2812,2839,2864,2882,2911,2929,2953,3069,3116,3148,3185,3221,3246,3270,3295,3319,3343,3369,3391,3413,3440,3458,3476,3499,3525,3543,3561,3584,3608,3632,3655,3673,3691,3716,3734,3752,3770,3794,3818,3836,3859,3883,3907,3931,3955,3980,3998,4019,4040,4064,4088,4111,4135,4160,4186,4211,4234,4257,4279,4303,4328,4357,4381,4399,4424,4442,4466,4484,4508,4531,4549,4572,4596,4620,4682,4719,4751,4773,4807,4834,4865,4887,4905,4930,4959,4977,4995,5013,5038,5061,5085,5110,5128,5151,5178,5202,5227,5245,5267,5285,5303,5321,5343,5371,5389,5407,5425,5450,5476,5499,5517,5541,5565,5583,5601,5625,5651,5675],{"intervention":45,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":119},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":44},[107],{"nctId":42,"briefTitle":43,"status":108,"phases":109,"primaryCompletion":44,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":117},"ACTIVE_NOT_RECRUITING",[90],"2026-12","2019-07-29",374,[114,115,116],"Renal Transplant Recipients","Elderly Patients","Immunosuppression",[45,118],"standard dose tacrolimus with mycophenolate mofetil",{"trials":120,"activeCount":98},[],{"intervention":118,"totalTrials":94,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":137},{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":98},[],{"trials":132,"activeCount":94,"soonestReadout":44},[133],{"nctId":42,"briefTitle":43,"status":108,"phases":134,"primaryCompletion":44,"completion":110,"start":111,"enrollment":112,"conditions":135,"interventions":136},[90],[114,115,116],[45,118],{"trials":138,"activeCount":98},[],{"intervention":50,"totalTrials":94,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":159},{"trials":142,"activeCount":98},[],{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":94,"soonestReadout":49},[151],{"nctId":47,"briefTitle":48,"status":152,"phases":153,"primaryCompletion":49,"completion":49,"start":154,"enrollment":155,"conditions":156,"interventions":158},"RECRUITING",[90],"2022-07-13",20,[157],"Lung Cancer",[50],{"trials":160,"activeCount":98},[],{"intervention":162,"totalTrials":94,"cells":163},"Patiromer 8400 MG [Veltassa]",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":186},{"trials":165,"activeCount":98},[],{"trials":167,"activeCount":98},[],{"trials":169,"activeCount":98},[],{"trials":171,"activeCount":98},[],{"trials":173,"activeCount":94,"soonestReadout":110},[174],{"nctId":175,"briefTitle":176,"status":152,"phases":177,"primaryCompletion":110,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":185},"NCT06256991","Potassium Correction for RAAS Optimization in Chronic Kidney Disease",[90],"2027-12","2024-04-01",44,[182,183,184],"Chronic Kidney Diseases","Hyperkalemia","Hypertension",[162],{"trials":187,"activeCount":98},[],{"intervention":189,"totalTrials":94,"cells":190},"Invokana 300 mg and 100 mg",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":212},{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":98},[],{"trials":200,"activeCount":94,"soonestReadout":206},[201],{"nctId":202,"briefTitle":203,"status":204,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":30,"conditions":208,"interventions":211},"NCT07527390","CANagliflozin In DIALysis Patients","NOT_YET_RECRUITING",[90],"2027-01-30","2026-06-01",[209,210],"Dialysis","Chronic Kidney Disease (Stages 4 and 5)",[189],{"trials":213,"activeCount":98},[],{"intervention":75,"totalTrials":94,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":237},{"trials":217,"activeCount":98},[],{"trials":219,"activeCount":98},[],{"trials":221,"activeCount":98},[],{"trials":223,"activeCount":98},[],{"trials":225,"activeCount":94,"soonestReadout":74},[226],{"nctId":72,"briefTitle":73,"status":152,"phases":227,"primaryCompletion":74,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":236},[90],"2026-12-31","2022-03-23",196,[232,233,157,234,235],"Drug Monitoring","Carcinoma, Non-Small-Cell Lung","Anaplastic Lymphoma Kinase Gene Mutation","Anaplastic Lymphoma Kinase Gene Translocation",[75],{"trials":238,"activeCount":98},[],{"intervention":84,"totalTrials":94,"cells":240},{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":262},{"trials":242,"activeCount":98},[],{"trials":244,"activeCount":98},[],{"trials":246,"activeCount":98},[],{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":94,"soonestReadout":79},[251],{"nctId":82,"briefTitle":83,"status":252,"phases":253,"primaryCompletion":79,"completion":79,"start":254,"enrollment":255,"conditions":256,"interventions":260},"ENROLLING_BY_INVITATION",[90],"2021-03-11",148,[257,258,259],"Inflammatory Bowel Diseases","Crohn Disease","Colitis, Ulcerative",[84,261],"Adalimumab",{"trials":263,"activeCount":98},[],{"intervention":261,"totalTrials":94,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":98},[],{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":94,"soonestReadout":79},[276],{"nctId":82,"briefTitle":83,"status":252,"phases":277,"primaryCompletion":79,"completion":79,"start":254,"enrollment":255,"conditions":278,"interventions":279},[90],[257,258,259],[84,261],{"trials":281,"activeCount":98},[],{"intervention":283,"totalTrials":284,"cells":285},"Leuprorelin",2,{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":304,"PHASE4":317,"NA":319},{"trials":287,"activeCount":98},[],{"trials":289,"activeCount":98},[],{"trials":291,"activeCount":94,"soonestReadout":296},[292],{"nctId":293,"briefTitle":294,"status":152,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":303},"NCT05478083","A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease",[88],"2027-06-01","2027-10-01","2022-06-01",36,[301,302],"Polycystic Liver Disease","Autosomal Dominant Polycystic Kidney",[283],{"trials":305,"activeCount":94,"soonestReadout":310},[306],{"nctId":307,"briefTitle":308,"status":108,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":316},"NCT04302454","Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy",[89],"2027-10-21","2027-12-01","2020-03-19",280,[315],"Prostate Cancer",[283],{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":98},[],{"intervention":322,"totalTrials":284,"cells":323},"Finerenone",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":342,"NA":366},{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"trials":331,"activeCount":94,"soonestReadout":336},[332],{"nctId":333,"briefTitle":334,"status":252,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":341},"NCT07181135","FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors",[89],"2027-12-31","2026-03-13",180,[340],"Chronic Kidney Disease",[322],{"trials":343,"activeCount":98},[344],{"nctId":345,"briefTitle":346,"status":347,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":22,"conditions":351,"interventions":364},"NCT06094920","Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","COMPLETED",[90],"2025-09-24","2024-07-29",[352,353,354,355,356,357,182,358,359,360,361,362,363],"Diabetes Mellitus Type 2 With Proteinuria","Diabetes Mellitus, Type 2","Diabetes Mellitus","Diabetes","Diabetes Complications","Albuminuria","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus","Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","CKD","CKD Stage 3","CKD Stage 4",[365,322],"Empagliflozin 10 MG",{"trials":367,"activeCount":98},[],{"intervention":369,"totalTrials":94,"cells":370},"Hydrochlorothiazide 25 mg",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":390,"NA":392},{"trials":372,"activeCount":98},[],{"trials":374,"activeCount":98},[],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":94,"soonestReadout":383},[379],{"nctId":380,"briefTitle":381,"status":152,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":389},"NCT05373264","HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life",[89],"2030-07","2031-07","2024-07-31",300,[388],"ADPKD",[369],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"intervention":395,"totalTrials":94,"cells":396},"Dapagliflozin 10 mg\u002Fday",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":418,"NA":420},{"trials":398,"activeCount":98},[],{"trials":400,"activeCount":98},[],{"trials":402,"activeCount":98},[],{"trials":404,"activeCount":94,"soonestReadout":409},[405],{"nctId":406,"briefTitle":407,"status":252,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":417},"NCT05374291","The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD",[89],"2027-07","2022-11-08",1750,[413,414,15,415,416],"Kidney Disease, Chronic","Renal Transplant Failure","Kidney Failure","Death",[395],{"trials":419,"activeCount":98},[],{"trials":421,"activeCount":98},[],{"intervention":423,"totalTrials":424,"cells":425},"cisplatin",4,{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":457,"PHASE4":459,"NA":461},{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":94,"soonestReadout":436},[432,446],{"nctId":433,"briefTitle":434,"status":152,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":444},"NCT05076942","Groningen International Study on Sentinel Nodes in Vulvar Cancer-III",[88],"2028-01-01","2029-01-01","2021-01-01",157,[441,442,443],"Vulvar Cancer","Sentinel Lymph Node","Lymph Node Metastases",[445],"Cisplatin",{"nctId":447,"briefTitle":448,"status":347,"phases":449,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT01088347","Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer",[87,88],"2014-03","2010-03",9,[454],"Advanced Cervical Cancer",[456,423],"mapatumumab",{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":94,"soonestReadout":39},[463,475],{"nctId":464,"briefTitle":465,"status":347,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":472},"NCT02778191","Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma",[],"2017-03","2016-02",413,[471],"Head and Neck Squamous Cell Carcinoma",[423,473,474],"carboplatin","5-FU",{"nctId":37,"briefTitle":38,"status":108,"phases":476,"primaryCompletion":39,"completion":477,"start":478,"enrollment":155,"conditions":479,"interventions":483},[],"2027-01","2017-12-12",[480,481,482],"Toxicity Due to Chemotherapy","Cardiovascular Morbidity","Cancer, Treatment-Related",[40,484,445,485],"Trastuzumab","Bleomycin",{"intervention":487,"totalTrials":488,"cells":489},"Dexamethasone",5,{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":506,"PHASE3":531,"PHASE4":544,"NA":557},{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[494],{"nctId":495,"briefTitle":496,"status":497,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":504},"NCT04733144","Bioequivalence Study of Prednisolone and Dexamethasone","UNKNOWN",[87],"2022-05-31","2021-03-04",24,[503],"Healthy Volunteers",[505,487],"Prednisolone",{"trials":507,"activeCount":94,"soonestReadout":512},[508,519],{"nctId":509,"briefTitle":510,"status":152,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":22,"conditions":515,"interventions":517},"NCT06616142","Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate",[87,88],"2026-10","2027-05","2024-11-06",[516],"Primary Aldosteronism",[518,487],"[18F]CETO tracer",{"nctId":520,"briefTitle":521,"status":347,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":528},"NCT02467010","Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance",[88],"2013-07","2008-09",73,[527],"Multiple Myeloma",[529,530,487],"Bortezomib","Cyclophosphamide",{"trials":532,"activeCount":98},[533],{"nctId":534,"briefTitle":535,"status":347,"phases":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT00127764","European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus",[88,89],"2005-04","2001-01",60,[541],"Pemphigus",[543],"dexamethasone",{"trials":545,"activeCount":98},[546],{"nctId":547,"briefTitle":548,"status":497,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT01275014","Corticosteroids as Additive in Temporomandibular Joint (TMJ) Arthrocentesis",[90],"2010-12","2008-12",28,[554],"Arthritis",[487,556],"Isotonic saline",{"trials":558,"activeCount":98},[],{"intervention":560,"totalTrials":284,"cells":561},"Dapagliflozin",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":94,"soonestReadout":178},[568,579],{"nctId":569,"briefTitle":570,"status":204,"phases":571,"primaryCompletion":178,"completion":572,"start":573,"enrollment":299,"conditions":574,"interventions":576},"NCT06072326","dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation",[88],"2028-12","2026-01",[575],"Type 1 Diabetes Mellitus With Diabetic Nephropathy",[560,577,578],"SC0062 strength 10mg","SC0062 and dapagliflozin",{"nctId":580,"briefTitle":581,"status":347,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":587},"NCT05570305","Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria",[88],"2025-03-05","2022-10-06",42,[182],[588,560,589],"Zibotentan","Dapagliflozin and Zibotentan",{"trials":591,"activeCount":98},[],{"trials":593,"activeCount":98},[],{"trials":595,"activeCount":98},[],{"intervention":597,"totalTrials":284,"cells":598},"Nivolumab",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":627,"PHASE4":629,"NA":631},{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":94,"soonestReadout":620},[605,616],{"nctId":606,"briefTitle":607,"status":608,"phases":609,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT02621515","Nivo\u002FIpi Combination Therapy in Symptomatic Brain Metastases","TERMINATED",[88],"2018-05-30","2016-08",7,[21,614],"Brain Metastasis",[597],{"nctId":617,"briefTitle":618,"status":152,"phases":619,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT06534190","CD8 PET Imaging in Metastatic Solid Tumours",[88],"2028-11","2025-03-11",30,[624],"Locally Advanced Solid Tumor",[597,626],"Cetrelimab",{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[],{"trials":632,"activeCount":98},[],{"intervention":634,"totalTrials":94,"cells":635},"Medical Cannabis",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":637,"activeCount":98},[],{"trials":639,"activeCount":98},[],{"trials":641,"activeCount":94,"soonestReadout":646},[642],{"nctId":643,"briefTitle":644,"status":152,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":155,"conditions":648,"interventions":651},"NCT06518434","A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients",[88],"2027-04-15","2021-04-15",[649,650],"Hepatocellular Carcinoma","Cannabis",[634],{"trials":653,"activeCount":98},[],{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"intervention":659,"totalTrials":94,"cells":660},"Survodutide",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":94,"soonestReadout":671},[667],{"nctId":668,"briefTitle":669,"status":204,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":675},"NCT07206290","Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease",[88],"2027-11-30","2026-03-02",120,[340],[659],{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"intervention":577,"totalTrials":94,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":685,"activeCount":98},[],{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":94,"soonestReadout":178},[690],{"nctId":569,"briefTitle":570,"status":204,"phases":691,"primaryCompletion":178,"completion":572,"start":573,"enrollment":299,"conditions":692,"interventions":693},[88],[575],[560,577,578],{"trials":695,"activeCount":98},[],{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[],{"intervention":578,"totalTrials":94,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":712,"PHASE4":714,"NA":716},{"trials":703,"activeCount":98},[],{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":94,"soonestReadout":178},[708],{"nctId":569,"briefTitle":570,"status":204,"phases":709,"primaryCompletion":178,"completion":572,"start":573,"enrollment":299,"conditions":710,"interventions":711},[88],[575],[560,577,578],{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"intervention":719,"totalTrials":94,"cells":720},"injection with 15 mg bevacizumab-800CW before bronchoscopy",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":722,"activeCount":98},[],{"trials":724,"activeCount":98},[],{"trials":726,"activeCount":94,"soonestReadout":731},[727],{"nctId":728,"briefTitle":729,"status":204,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":155,"conditions":733,"interventions":738},"NCT06809946","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy",[88],"2028-08-17","2026-08-17",[734,735,736,737],"Lung Neoplasms","Pulmonary Neoplasms","Lymph Node Involvement","Pulmonary Nodule",[719,739],"injection with 25 mg bevacizumab-800CW before bronchoscopy",{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":98},[],{"trials":745,"activeCount":98},[],{"intervention":739,"totalTrials":94,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":749,"activeCount":98},[],{"trials":751,"activeCount":98},[],{"trials":753,"activeCount":94,"soonestReadout":731},[754],{"nctId":728,"briefTitle":729,"status":204,"phases":755,"primaryCompletion":731,"completion":731,"start":732,"enrollment":155,"conditions":756,"interventions":757},[88],[734,735,736,737],[719,739],{"trials":759,"activeCount":98},[],{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":98},[],{"intervention":765,"totalTrials":94,"cells":766},"vicadrostat \u002F empagliflozin combination 1",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":94,"soonestReadout":777},[773],{"nctId":774,"briefTitle":775,"status":152,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT07304817","Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)",[88],"2028-02","2026-05-12",100,[361,781,15],"Cardiovascular Diseases",[765,783],"Spironolactone",{"trials":785,"activeCount":98},[],{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":98},[],{"intervention":783,"totalTrials":94,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[],{"trials":797,"activeCount":94,"soonestReadout":777},[798],{"nctId":774,"briefTitle":775,"status":152,"phases":799,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":800,"interventions":801},[88],[361,781,15],[765,783],{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"intervention":70,"totalTrials":94,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":824,"PHASE4":826,"NA":828},{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":94,"soonestReadout":69},[816],{"nctId":67,"briefTitle":68,"status":152,"phases":817,"primaryCompletion":69,"completion":178,"start":818,"enrollment":386,"conditions":819,"interventions":822},[88],"2022-10-18",[820,821],"NHL","DLBCL - Diffuse Large B Cell Lymphoma",[70,823],"Axi-cel",{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":98},[],{"trials":829,"activeCount":98},[],{"intervention":823,"totalTrials":94,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":94,"soonestReadout":69},[838],{"nctId":67,"briefTitle":68,"status":152,"phases":839,"primaryCompletion":69,"completion":178,"start":818,"enrollment":386,"conditions":840,"interventions":841},[88],[820,821],[70,823],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"intervention":518,"totalTrials":94,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":94,"soonestReadout":512},[856],{"nctId":509,"briefTitle":510,"status":152,"phases":857,"primaryCompletion":512,"completion":513,"start":514,"enrollment":22,"conditions":858,"interventions":859},[87,88],[516],[518,487],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"intervention":867,"totalTrials":94,"cells":868},"25mg adalimumab-680LT and 15\u002F25 mg risankizumab-800CW",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":870,"activeCount":98},[],{"trials":872,"activeCount":98},[],{"trials":874,"activeCount":94,"soonestReadout":336},[875],{"nctId":876,"briefTitle":877,"status":204,"phases":878,"primaryCompletion":336,"completion":879,"start":880,"enrollment":622,"conditions":881,"interventions":884},"NCT07258641","Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease",[87,88],"2028-04-01","2026-01-15",[882,883],"Ulcerative Colitis (UC)","Crohn Disease (CD)",[867,885,886],"Adalimumab-680LT 25mg","Risankizumab-800CW 15 mg\u002F25 mg",{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":98},[],{"intervention":885,"totalTrials":94,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":94,"soonestReadout":336},[901],{"nctId":876,"briefTitle":877,"status":204,"phases":902,"primaryCompletion":336,"completion":879,"start":880,"enrollment":622,"conditions":903,"interventions":904},[87,88],[882,883],[867,885,886],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[],{"intervention":886,"totalTrials":94,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":94,"soonestReadout":336},[919],{"nctId":876,"briefTitle":877,"status":204,"phases":920,"primaryCompletion":336,"completion":879,"start":880,"enrollment":622,"conditions":921,"interventions":922},[87,88],[882,883],[867,885,886],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":98},[],{"trials":928,"activeCount":98},[],{"intervention":930,"totalTrials":94,"cells":931},"Pembrolizumab Injection [Keytruda]",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":933,"activeCount":98},[],{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":94,"soonestReadout":942},[938],{"nctId":939,"briefTitle":940,"status":108,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":22,"conditions":945,"interventions":947},"NCT06180733","Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer",[88],"2027-12-30","2028-01","2023-12-01",[946],"Endometrial Cancer",[930],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[],{"intervention":955,"totalTrials":94,"cells":956},"Psilocybin therapy",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":94,"soonestReadout":967},[963],{"nctId":964,"briefTitle":965,"status":152,"phases":966,"primaryCompletion":967,"completion":436,"start":968,"enrollment":969,"conditions":970,"interventions":976},"NCT06782724","Psilocybin Therapy for Psychological Distress in Palliative Patients",[88],"2027-01-01","2025-07-01",108,[971,972,973,974,975],"COPD (Chronic Obstructive Pulmonary Disease)","ALS (Amyotrophic Lateral Sclerosis)","MS (Multiple Sclerosis)","Major Depressive Disorder (MDD)","Atypical Parkinson Disease",[955],{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[],{"trials":982,"activeCount":98},[],{"intervention":55,"totalTrials":94,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":94,"soonestReadout":54},[991],{"nctId":52,"briefTitle":53,"status":152,"phases":992,"primaryCompletion":54,"completion":69,"start":993,"enrollment":16,"conditions":994,"interventions":995},[87,88],"2024-11-08",[882,883],[55,996,997,998],"Risankizumab-800CW 15 mg","Risankizumab-800CW 25 mg","Risankizumab-800CW optimal dose",{"trials":1000,"activeCount":98},[],{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"intervention":996,"totalTrials":94,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":94,"soonestReadout":54},[1013],{"nctId":52,"briefTitle":53,"status":152,"phases":1014,"primaryCompletion":54,"completion":69,"start":993,"enrollment":16,"conditions":1015,"interventions":1016},[87,88],[882,883],[55,996,997,998],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"intervention":997,"totalTrials":94,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":94,"soonestReadout":54},[1031],{"nctId":52,"briefTitle":53,"status":152,"phases":1032,"primaryCompletion":54,"completion":69,"start":993,"enrollment":16,"conditions":1033,"interventions":1034},[87,88],[882,883],[55,996,997,998],{"trials":1036,"activeCount":98},[],{"trials":1038,"activeCount":98},[],{"trials":1040,"activeCount":98},[],{"intervention":998,"totalTrials":94,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":94,"soonestReadout":54},[1049],{"nctId":52,"briefTitle":53,"status":152,"phases":1050,"primaryCompletion":54,"completion":69,"start":993,"enrollment":16,"conditions":1051,"interventions":1052},[87,88],[882,883],[55,996,997,998],{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"intervention":80,"totalTrials":94,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1062,"activeCount":98},[],{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":94,"soonestReadout":79},[1067],{"nctId":77,"briefTitle":78,"status":152,"phases":1068,"primaryCompletion":79,"completion":1069,"start":1070,"enrollment":299,"conditions":1071,"interventions":1074},[88],"2026-08-01","2024-08-06",[1072,1073],"IBD","Rheumatoid Arthritis",[80],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[],{"trials":1080,"activeCount":98},[],{"intervention":65,"totalTrials":94,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":94,"soonestReadout":64},[1089],{"nctId":62,"briefTitle":63,"status":108,"phases":1090,"primaryCompletion":64,"completion":64,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1095},[87,88],"2022-01-18",41,[1094],"Metastatic Solid Tumor",[65],{"trials":1097,"activeCount":98},[],{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":98},[],{"intervention":1103,"totalTrials":94,"cells":1104},"Indocyanine Green",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1121,"PHASE4":1123,"NA":1125},{"trials":1106,"activeCount":98},[],{"trials":1108,"activeCount":98},[],{"trials":1110,"activeCount":94,"soonestReadout":296},[1111],{"nctId":1112,"briefTitle":1113,"status":152,"phases":1114,"primaryCompletion":296,"completion":1115,"start":1116,"enrollment":30,"conditions":1117,"interventions":1120},"NCT07108855","Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection",[87,88],"2027-08-01","2025-09-01",[1118,1119],"Esophageal Carcinoma","Gastric Carcinoma",[1103],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[],{"trials":1126,"activeCount":98},[],{"intervention":1128,"totalTrials":94,"cells":1129},"Avastin",{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1131,"activeCount":98},[],{"trials":1133,"activeCount":98},[],{"trials":1135,"activeCount":94,"soonestReadout":1140},[1136],{"nctId":1137,"briefTitle":1138,"status":152,"phases":1139,"primaryCompletion":1140,"completion":110,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1147},"NCT05745857","Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas",[88],"2026-05","2023-09-15",25,[1144,1145,1146],"Barrett's Esophagus Without Dysplasia","Barrett Oesophagitis With Dysplasia","Esophageal Adenocarcinoma",[1128,1148],"Erbitux",{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[],{"intervention":1148,"totalTrials":94,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":98},[],{"trials":1162,"activeCount":94,"soonestReadout":1140},[1163],{"nctId":1137,"briefTitle":1138,"status":152,"phases":1164,"primaryCompletion":1140,"completion":110,"start":1141,"enrollment":1142,"conditions":1165,"interventions":1166},[88],[1144,1145,1146],[1128,1148],{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"intervention":626,"totalTrials":94,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":94,"soonestReadout":620},[1181],{"nctId":617,"briefTitle":618,"status":152,"phases":1182,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":1183,"interventions":1184},[88],[624],[597,626],{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"intervention":60,"totalTrials":94,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[],{"trials":1198,"activeCount":94,"soonestReadout":59},[1199],{"nctId":57,"briefTitle":58,"status":152,"phases":1200,"primaryCompletion":59,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1207},[88],"2027-09","2023-10-18",97,[1205,1206,21],"Head and Neck Neoplasms","MSI-H Cancer",[60],{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"intervention":1215,"totalTrials":284,"cells":1216},"Ustekinumab",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1232,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":94,"soonestReadout":1225},[1221],{"nctId":1222,"briefTitle":1223,"status":152,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT05725876","Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.",[87],"2026-07-01","2027-01-06","2025-01-06",56,[1230,258],"Psoriasis",[1215],{"trials":1233,"activeCount":98},[1234],{"nctId":1235,"briefTitle":1236,"status":347,"phases":1237,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":155,"conditions":1241,"interventions":1243},"NCT01704534","A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa",[88],"2014-01","2014-04","2012-05",[1242],"Hidradenitis Suppurativa",[1215],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"intervention":1251,"totalTrials":94,"cells":1252},"Nivolumab-800CW",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":94,"soonestReadout":1261},[1257],{"nctId":1258,"briefTitle":1259,"status":204,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT07196384","Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW",[87],"2026-10-30","2026-12-30","2025-12-15",15,[26],[1251,1267],"Durvalumab-680LT",{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"intervention":1267,"totalTrials":94,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":94,"soonestReadout":1261},[1282],{"nctId":1258,"briefTitle":1259,"status":204,"phases":1283,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1284,"interventions":1285},[87],[26],[1251,1267],{"trials":1287,"activeCount":98},[],{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"intervention":40,"totalTrials":94,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1297,"activeCount":98},[],{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":94,"soonestReadout":39},[1308],{"nctId":37,"briefTitle":38,"status":108,"phases":1309,"primaryCompletion":39,"completion":477,"start":478,"enrollment":155,"conditions":1310,"interventions":1311},[],[480,481,482],[40,484,445,485],{"intervention":484,"totalTrials":94,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1315,"activeCount":98},[],{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":94,"soonestReadout":39},[1326],{"nctId":37,"briefTitle":38,"status":108,"phases":1327,"primaryCompletion":39,"completion":477,"start":478,"enrollment":155,"conditions":1328,"interventions":1329},[],[480,481,482],[40,484,445,485],{"intervention":485,"totalTrials":94,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":94,"soonestReadout":39},[1344],{"nctId":37,"briefTitle":38,"status":108,"phases":1345,"primaryCompletion":39,"completion":477,"start":478,"enrollment":155,"conditions":1346,"interventions":1347},[],[480,481,482],[40,484,445,485],{"intervention":1349,"totalTrials":94,"cells":1350},"Euthyrox",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":94,"soonestReadout":1367},[1363],{"nctId":1364,"briefTitle":1365,"status":204,"phases":1366,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1377},"NCT06647602","Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy",[],"2028-03-31","2028-12-31","2026-09-01",40,[1372,1373,1374,1375,1376],"Differentiated Thyroid Cancer","Thyroid Cancer","Levothyroxine","Liothyronine","Thyroid Hormones",[1349,1378],"Cytomel",{"intervention":1378,"totalTrials":94,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":94,"soonestReadout":1367},[1393],{"nctId":1364,"briefTitle":1365,"status":204,"phases":1394,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":1395,"interventions":1396},[],[1372,1373,1374,1375,1376],[1349,1378],{"intervention":1398,"totalTrials":94,"cells":1399},"Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[],{"trials":1405,"activeCount":98},[],{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":94,"soonestReadout":297},[1412],{"nctId":1413,"briefTitle":1414,"status":152,"phases":1415,"primaryCompletion":297,"completion":1416,"start":1116,"enrollment":1417,"conditions":1418,"interventions":1419},"NCT06484491","IMPT Dose Escalation for NSCLC (HyDose)",[91],"2028-10-01",87,[233],[1398,1420],"Immunotherapy: adjuvant durvalumab",{"intervention":1420,"totalTrials":94,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"trials":1428,"activeCount":98},[],{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":94,"soonestReadout":297},[1435],{"nctId":1413,"briefTitle":1414,"status":152,"phases":1436,"primaryCompletion":297,"completion":1416,"start":1116,"enrollment":1417,"conditions":1437,"interventions":1438},[91],[233],[1398,1420],{"intervention":1440,"totalTrials":94,"cells":1441},"Pharmacological rhythm management",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1450,"NA":1452},{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":94,"soonestReadout":1458},[1454],{"nctId":1455,"briefTitle":1456,"status":152,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1464},"NCT06200311","Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men",[91],"2029-07-25","2024-07-25",604,[1462,1463],"Fibrillation, Atrial","Atrial Cardiomyopathy",[1440],{"intervention":556,"totalTrials":284,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1492},{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":98},[],{"trials":1476,"activeCount":98},[1477,1488],{"nctId":1478,"briefTitle":1479,"status":608,"phases":1480,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1486},"NCT02902055","Paediatric Ards Neuromuscular Blockade Study",[90],"2024-05-01","2019-12-01",3,[1485],"ARDS",[1487,556],"Neuromuscular Blocking Agents",{"nctId":547,"briefTitle":548,"status":497,"phases":1489,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":1490,"interventions":1491},[90],[554],[487,556],{"trials":1493,"activeCount":98},[],{"intervention":365,"totalTrials":284,"cells":1495},{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1514,"PHASE4":1516,"NA":1522},{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[1502],{"nctId":1503,"briefTitle":1504,"status":347,"phases":1505,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":1509,"interventions":1513},"NCT03200860","Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure",[88],"2019-09-18","2017-12-18",80,[1510,1511,1512],"Heart Failure Acute","Heart Failure，Congestive","Heart Failure; With Decompensation",[365],{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[1518],{"nctId":345,"briefTitle":346,"status":347,"phases":1519,"primaryCompletion":349,"completion":349,"start":350,"enrollment":22,"conditions":1520,"interventions":1521},[90],[352,353,354,355,356,357,182,358,359,360,361,362,363],[365,322],{"trials":1523,"activeCount":98},[],{"intervention":1525,"totalTrials":284,"cells":1526},"Palbociclib",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1542,"PHASE4":1544,"NA":1563},{"trials":1528,"activeCount":98},[],{"trials":1530,"activeCount":98},[],{"trials":1532,"activeCount":98},[1533],{"nctId":1534,"briefTitle":1535,"status":347,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":622,"conditions":1539,"interventions":1540},"NCT02806050","Palbociclib and FES PET",[88],"2022-09-28","2016-09-16",[18],[1525,1541],"Letrozole",{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[1546],{"nctId":1547,"briefTitle":1548,"status":497,"phases":1549,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":622,"conditions":1552,"interventions":1558},"NCT05949424","OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",[90],"2025-03","2024-05",[1553,1554,1555,1556,1557],"Renal Cell Carcinoma","Ovarian Carcinoma","Thyroid Carcinoma","Breast Carcinoma","Endometrium Carcinoma",[1559,1560,1561,1525,1562,1559,1560,1561,1525,1562],"Olaparib","Lenvatinib","Sunitinib","Pazopanib",{"trials":1564,"activeCount":98},[],{"intervention":1566,"totalTrials":284,"cells":1567},"azathioprine",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1588,"NA":1601},{"trials":1569,"activeCount":98},[],{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[1576],{"nctId":1577,"briefTitle":1578,"status":497,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1585},"NCT03026907","Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema",[89],"2019-12","2016-05",116,[1584],"Hand Eczema",[1586,1587],"Alitretinoin","Azathioprine",{"trials":1589,"activeCount":98},[1590],{"nctId":1591,"briefTitle":1592,"status":608,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1600},"NCT00128895","Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis",[90],"2014-06","2014-12","2003-06",131,[1599],"Vasculitis",[1566],{"trials":1602,"activeCount":98},[],{"intervention":1604,"totalTrials":284,"cells":1605},"Dapagliflozin 10Mg Tab",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1620,"PHASE4":1622,"NA":1634},{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[1612],{"nctId":1613,"briefTitle":1614,"status":608,"phases":1615,"primaryCompletion":1616,"completion":1616,"start":1617,"enrollment":452,"conditions":1618,"interventions":1619},"NCT05268926","TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension",[88],"2023-02-02","2022-02-03",[357],[1604],{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[1624],{"nctId":1625,"briefTitle":1626,"status":347,"phases":1627,"primaryCompletion":1628,"completion":1628,"start":1629,"enrollment":155,"conditions":1630,"interventions":1632},"NCT06374043","Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.",[90],"2022-09-13","2021-05-11",[353,352,354,355,356,357,182,358,361,1631],"Proteinuria",[1633],"Dapagliflozin 10mg Tab",{"trials":1635,"activeCount":98},[],{"intervention":1637,"totalTrials":94,"cells":1638},"Dexmedetomidine",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1659},{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[],{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":98},[1649],{"nctId":1650,"briefTitle":1651,"status":347,"phases":1652,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":622,"conditions":1655,"interventions":1657},"NCT03143972","Pharmacodynamic Interaction of REMI and DMED",[90],"2018-02-23","2017-06-28",[1656],"Anesthesia",[1637,1658],"Remifentanil",{"trials":1660,"activeCount":98},[],{"intervention":1487,"totalTrials":94,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1669,"PHASE4":1671,"NA":1677},{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":98},[],{"trials":1672,"activeCount":98},[1673],{"nctId":1478,"briefTitle":1479,"status":608,"phases":1674,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1675,"interventions":1676},[90],[1485],[1487,556],{"trials":1678,"activeCount":98},[],{"intervention":1680,"totalTrials":94,"cells":1681},"Caspofungin",{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1690,"NA":1702},{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[1692],{"nctId":1693,"briefTitle":1694,"status":347,"phases":1695,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":155,"conditions":1698,"interventions":1701},"NCT01994096","Optimal Dosage of Caspofungin in Critically Ill Patients",[90],"2015-10","2013-11",[1699,1700],"Critically Ill","Suspected Invasive Candidiasis",[1680],{"trials":1703,"activeCount":98},[],{"intervention":1705,"totalTrials":94,"cells":1706},"bosentan",{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1715,"NA":1726},{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[],{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[1717],{"nctId":1718,"briefTitle":1719,"status":347,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":155,"conditions":1723,"interventions":1725},"NCT02480335","The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis",[90],"2018-07-30","2015-06-26",[1724],"Scleroderma, Systemic",[1705],{"trials":1727,"activeCount":98},[],{"intervention":1729,"totalTrials":94,"cells":1730},"COVID-19 vaccination",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1754},{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[1741],{"nctId":1742,"briefTitle":1743,"status":347,"phases":1744,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1753},"NCT05924685","PREPARE-iVAC Trial",[90],"2023-12-29","2024-02-27","2023-08-22",110,[1750,1751,1752,116],"COVID-19 Vaccines","Varicella Zoster Vaccine","Vaccine Response",[1729],{"trials":1755,"activeCount":98},[],{"intervention":1757,"totalTrials":94,"cells":1758},"Hydrocortisone",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1779},{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":98},[],{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[1769],{"nctId":1770,"briefTitle":1771,"status":347,"phases":1772,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1778},"NCT01546922","Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)",[90],"2013-06","2012-02",63,[1777],"Adrenal Insufficiency",[1757],{"trials":1780,"activeCount":98},[],{"intervention":1782,"totalTrials":94,"cells":1783},"Beclomethasone",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1804},{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[1794],{"nctId":1795,"briefTitle":1796,"status":347,"phases":1797,"primaryCompletion":1798,"completion":1799,"start":1800,"enrollment":1370,"conditions":1801,"interventions":1802},"NCT01741285","Effects of QVAR in Smokers With Asthma",[90],"2015-07","2015-12","2013-04",[34],[1782,1782,1803],"Fluticasone",{"trials":1805,"activeCount":98},[],{"intervention":1803,"totalTrials":94,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1822},{"trials":1809,"activeCount":98},[],{"trials":1811,"activeCount":98},[],{"trials":1813,"activeCount":98},[],{"trials":1815,"activeCount":98},[],{"trials":1817,"activeCount":98},[1818],{"nctId":1795,"briefTitle":1796,"status":347,"phases":1819,"primaryCompletion":1798,"completion":1799,"start":1800,"enrollment":1370,"conditions":1820,"interventions":1821},[90],[34],[1782,1782,1803],{"trials":1823,"activeCount":98},[],{"intervention":1825,"totalTrials":94,"cells":1826},"Benfotiamine",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1847},{"trials":1828,"activeCount":98},[],{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[1837],{"nctId":1838,"briefTitle":1839,"status":347,"phases":1840,"primaryCompletion":1841,"completion":1841,"start":1842,"enrollment":1843,"conditions":1844,"interventions":1846},"NCT00565318","Benfotiamine in Diabetic Nephropathy",[90],"2009-06","2007-12",86,[1845],"Diabetic Nephropathy",[1825],{"trials":1848,"activeCount":98},[],{"intervention":1850,"totalTrials":94,"cells":1851},"Moxifloxacin",{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1858,"PHASE4":1860,"NA":1871},{"trials":1853,"activeCount":98},[],{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[1862],{"nctId":1863,"briefTitle":1864,"status":608,"phases":1865,"primaryCompletion":1866,"completion":611,"start":1867,"enrollment":452,"conditions":1868,"interventions":1870},"NCT01329250","Pharmacokinetics and Safety of Moxifloxacin",[90],"2015-06","2011-05",[1869],"Tuberculosis",[1850],{"trials":1872,"activeCount":98},[],{"intervention":1874,"totalTrials":94,"cells":1875},"Cefotaxime",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1884,"NA":1895},{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[1886],{"nctId":1887,"briefTitle":1888,"status":347,"phases":1889,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":539,"conditions":1893,"interventions":1894},"NCT02560207","Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.",[90],"2016-06","2016-09","2015-11",[1699],[1874],{"trials":1896,"activeCount":98},[],{"intervention":1898,"totalTrials":94,"cells":1899},"sevoflurane",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1929},{"trials":1901,"activeCount":98},[],{"trials":1903,"activeCount":98},[],{"trials":1905,"activeCount":98},[],{"trials":1907,"activeCount":98},[],{"trials":1909,"activeCount":98},[1910],{"nctId":1911,"briefTitle":1912,"status":347,"phases":1913,"primaryCompletion":1914,"completion":1915,"start":1916,"enrollment":1917,"conditions":1918,"interventions":1927},"NCT02727296","Volatile Anesthetic Protection Of Renal Transplants 2",[90],"2025-01-30","2025-01-31","2017-04-01",488,[1919,1920,1921,1922,1923,1924,1925,1926],"Delayed Graft Function","Renal Outcome After Kidney Transplantation","Acute Rejection (AR) of Transplanted Kidney","Graft Survival","Patient Survival","Postoperative Complications","Length of Hospital Stay","Primary Non Function",[1898,1928],"propofol",{"trials":1930,"activeCount":98},[],{"intervention":1932,"totalTrials":94,"cells":1933},"tacrolimus OD, mycophenolic acid, prednisolone",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1956},{"trials":1935,"activeCount":98},[],{"trials":1937,"activeCount":98},[],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[1944],{"nctId":1945,"briefTitle":1946,"status":347,"phases":1947,"primaryCompletion":1948,"completion":1949,"start":1950,"enrollment":1951,"conditions":1952,"interventions":1955},"NCT01560572","Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen",[90],"2015-04","2016-04","2011-04",305,[1953,1954],"Renal Insufficiency","Kidney Transplantation",[1932],{"trials":1957,"activeCount":98},[],{"intervention":1559,"totalTrials":94,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1968,"NA":1974},{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[],{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[1970],{"nctId":1547,"briefTitle":1548,"status":497,"phases":1971,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":622,"conditions":1972,"interventions":1973},[90],[1553,1554,1555,1556,1557],[1559,1560,1561,1525,1562,1559,1560,1561,1525,1562],{"trials":1975,"activeCount":98},[],{"intervention":1560,"totalTrials":94,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":1992},{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[1988],{"nctId":1547,"briefTitle":1548,"status":497,"phases":1989,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":622,"conditions":1990,"interventions":1991},[90],[1553,1554,1555,1556,1557],[1559,1560,1561,1525,1562,1559,1560,1561,1525,1562],{"trials":1993,"activeCount":98},[],{"intervention":1561,"totalTrials":94,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2010},{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[2006],{"nctId":1547,"briefTitle":1548,"status":497,"phases":2007,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":622,"conditions":2008,"interventions":2009},[90],[1553,1554,1555,1556,1557],[1559,1560,1561,1525,1562,1559,1560,1561,1525,1562],{"trials":2011,"activeCount":98},[],{"intervention":1562,"totalTrials":94,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2028},{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[2024],{"nctId":1547,"briefTitle":1548,"status":497,"phases":2025,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":622,"conditions":2026,"interventions":2027},[90],[1553,1554,1555,1556,1557],[1559,1560,1561,1525,1562,1559,1560,1561,1525,1562],{"trials":2029,"activeCount":98},[],{"intervention":2031,"totalTrials":94,"cells":2032},"Tiotropium Bromide",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2052},{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":98},[],{"trials":2040,"activeCount":98},[],{"trials":2042,"activeCount":98},[2043],{"nctId":2044,"briefTitle":2045,"status":347,"phases":2046,"primaryCompletion":2047,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2051},"NCT04061161","Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD",[90],"2023-12-31","2019-08-19",37,[24],[2031],{"trials":2053,"activeCount":98},[],{"intervention":2055,"totalTrials":94,"cells":2056},"mRNA-1273",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2065,"NA":2081},{"trials":2058,"activeCount":98},[],{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[2067],{"nctId":2068,"briefTitle":2069,"status":347,"phases":2070,"primaryCompletion":2071,"completion":2071,"start":2072,"enrollment":2073,"conditions":2074,"interventions":2079},"NCT05030974","RECOVAC Repeated Vaccination Study",[90],"2022-03-12","2021-10-21",336,[2075,2076,2077,2078],"Covid19","Kidney Diseases","Vaccine Response Impaired","SARS-CoV2 Infection",[2055,2080],"Ad26.COV2.S vaccine",{"trials":2082,"activeCount":98},[],{"intervention":2080,"totalTrials":94,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2099},{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[2095],{"nctId":2068,"briefTitle":2069,"status":347,"phases":2096,"primaryCompletion":2071,"completion":2071,"start":2072,"enrollment":2073,"conditions":2097,"interventions":2098},[90],[2075,2076,2077,2078],[2055,2080],{"trials":2100,"activeCount":98},[],{"intervention":2102,"totalTrials":94,"cells":2103},"Potassium Chloride",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2125},{"trials":2105,"activeCount":98},[],{"trials":2107,"activeCount":98},[],{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[2114],{"nctId":2115,"briefTitle":2116,"status":347,"phases":2117,"primaryCompletion":2118,"completion":2119,"start":1841,"enrollment":2120,"conditions":2121,"interventions":2124},"NCT01085071","Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients",[90],"2011-12","2012-01",1225,[2122,2123,1699],"Thoracic Surgery","Cardiac Surgery",[2102,2102],{"trials":2126,"activeCount":98},[],{"intervention":2128,"totalTrials":94,"cells":2129},"withdrawal or continuation of amiodarone therapy",{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2134,"PHASE3":2136,"PHASE4":2138,"NA":2148},{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"trials":2135,"activeCount":98},[],{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":98},[2140],{"nctId":2141,"briefTitle":2142,"status":347,"phases":2143,"primaryCompletion":1841,"completion":1841,"start":2144,"enrollment":2049,"conditions":2145,"interventions":2147},"NCT00845780","Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation",[90],"2000-08",[2146],"Persistent Atrial Fibrillation",[2128],{"trials":2149,"activeCount":98},[],{"intervention":2151,"totalTrials":94,"cells":2152},"Addition of different doses of clarithromycin.",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2173},{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[],{"trials":2162,"activeCount":98},[2163],{"nctId":2164,"briefTitle":2165,"status":347,"phases":2166,"primaryCompletion":2167,"completion":2168,"start":2118,"enrollment":612,"conditions":2169,"interventions":2172},"NCT01521364","Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients",[90],"2012-10","2012-11",[2170,2171],"Multidrug-resistant Tuberculosis","Extensively Drug-resistant Tuberculosis",[2151],{"trials":2174,"activeCount":98},[],{"intervention":2176,"totalTrials":94,"cells":2177},"Phenoxybenzamine",{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2186,"NA":2198},{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[2188],{"nctId":2189,"briefTitle":2190,"status":347,"phases":2191,"primaryCompletion":2192,"completion":2192,"start":2118,"enrollment":2193,"conditions":2194,"interventions":2196},"NCT01379898","Phenoxybenzamine Versus Doxazosin in PCC Patients",[90],"2018-01",134,[2195],"Pheochromocytoma",[2176,2197],"Doxazosin",{"trials":2199,"activeCount":98},[],{"intervention":2197,"totalTrials":94,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2216},{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":98},[2212],{"nctId":2189,"briefTitle":2190,"status":347,"phases":2213,"primaryCompletion":2192,"completion":2192,"start":2118,"enrollment":2193,"conditions":2214,"interventions":2215},[90],[2195],[2176,2197],{"trials":2217,"activeCount":98},[],{"intervention":2219,"totalTrials":94,"cells":2220},"amoxicillin 500 mg + metronidazole 500 mg",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2241},{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[2231],{"nctId":2232,"briefTitle":2233,"status":347,"phases":2234,"primaryCompletion":1580,"completion":1580,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2240},"NCT04149327","Systemic Amoxicillin Plus Metronidazole in Peri-implantitis Treatment",[90],"2012-08-01",62,[2238,2239],"Peri-implantitis","Periodontal Diseases",[2219],{"trials":2242,"activeCount":98},[],{"intervention":2244,"totalTrials":94,"cells":2245},"Digoxin",{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2266},{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[],{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[2256],{"nctId":2257,"briefTitle":2258,"status":347,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2263,"interventions":2264},"NCT03783429","Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands",[90],"2025-11-13","2020-07-01",982,[15],[2244,2265],"Placebos",{"trials":2267,"activeCount":98},[],{"intervention":2265,"totalTrials":94,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2284},{"trials":2271,"activeCount":98},[],{"trials":2273,"activeCount":98},[],{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[2280],{"nctId":2257,"briefTitle":2258,"status":347,"phases":2281,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2282,"interventions":2283},[90],[15],[2244,2265],{"trials":2285,"activeCount":98},[],{"intervention":530,"totalTrials":1483,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2309,"PHASE4":2323,"NA":2325},{"trials":2289,"activeCount":98},[],{"trials":2291,"activeCount":98},[],{"trials":2293,"activeCount":98},[2294,2305],{"nctId":2295,"briefTitle":2296,"status":347,"phases":2297,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":2300,"conditions":2301,"interventions":2303},"NCT00844506","p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer",[88],"2009-07","2008-10",19,[2302],"Ovarian Cancer",[2304,530],"P53-SLP vaccine",{"nctId":520,"briefTitle":521,"status":347,"phases":2306,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":2307,"interventions":2308},[88],[527],[529,530,487],{"trials":2310,"activeCount":98},[2311],{"nctId":2312,"briefTitle":2313,"status":347,"phases":2314,"primaryCompletion":1595,"completion":2315,"start":2316,"enrollment":2317,"conditions":2318,"interventions":2320},"NCT00103792","Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)",[89],"2015-01","2004-12",84,[2319,1599],"Wegener's Granulomatosis",[2321,2322],"mycophenolate mofetil","cyclophosphamide",{"trials":2324,"activeCount":98},[],{"trials":2326,"activeCount":98},[],{"intervention":1586,"totalTrials":284,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2351,"NA":2353},{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[2337,2347],{"nctId":2338,"briefTitle":2339,"status":497,"phases":2340,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":2343,"conditions":2344,"interventions":2345},"NCT03026946","Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema",[89],"2022-07","2017-05-29",76,[1584],[1586,2346],"cyclosporin A",{"nctId":1577,"briefTitle":1578,"status":497,"phases":2348,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2349,"interventions":2350},[89],[1584],[1586,1587],{"trials":2352,"activeCount":98},[],{"trials":2354,"activeCount":98},[],{"intervention":2356,"totalTrials":284,"cells":2357},"Metformin",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2373,"PHASE3":2375,"PHASE4":2388,"NA":2390},{"trials":2359,"activeCount":98},[],{"trials":2361,"activeCount":98},[2362],{"nctId":2363,"briefTitle":2364,"status":347,"phases":2365,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":1264,"conditions":2368,"interventions":2370},"NCT02312661","Study of Metformin With Carboplatin\u002FPaclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer",[87],"2017-11","2015-10-05",[2369],"Epithelial Ovarian Cancer",[2356,2371,2372],"Carboplatin","Paclitaxel",{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[2377],{"nctId":2378,"briefTitle":2379,"status":347,"phases":2380,"primaryCompletion":2381,"completion":1696,"start":2382,"enrollment":2383,"conditions":2384,"interventions":2387},"NCT01217307","Metformin to Reduce Heart Failure After Myocardial Infarction",[88,89],"2013-10","2011-01",380,[2385,2386,15,355],"ST Elevation Myocardial Infarction (STEMI)","Coronary Artery Disease",[2356],{"trials":2389,"activeCount":98},[],{"trials":2391,"activeCount":98},[],{"intervention":2321,"totalTrials":94,"cells":2393},{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2406,"NA":2408},{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[],{"trials":2401,"activeCount":98},[2402],{"nctId":2312,"briefTitle":2313,"status":347,"phases":2403,"primaryCompletion":1595,"completion":2315,"start":2316,"enrollment":2317,"conditions":2404,"interventions":2405},[89],[2319,1599],[2321,2322],{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[],{"intervention":2411,"totalTrials":94,"cells":2412},"Fosinopril",{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2417,"PHASE3":2419,"PHASE4":2435,"NA":2437},{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"trials":2418,"activeCount":98},[],{"trials":2420,"activeCount":98},[2421],{"nctId":2422,"briefTitle":2423,"status":347,"phases":2424,"primaryCompletion":1596,"completion":2425,"start":2426,"enrollment":2427,"conditions":2428,"interventions":2431},"NCT03073018","Prevention of Renal and Vascular Endstage Disease Intervention Trial",[89],"2003-11","1998-04",864,[2429,781,2430],"Microalbuminuria","Renal Disease",[2411,2432,2433,2434],"Pravastatin","Fosinopril Placebo","Pravastatin Placebo",{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"intervention":2432,"totalTrials":94,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2447,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":98},[],{"trials":2444,"activeCount":98},[],{"trials":2446,"activeCount":98},[],{"trials":2448,"activeCount":98},[2449],{"nctId":2422,"briefTitle":2423,"status":347,"phases":2450,"primaryCompletion":1596,"completion":2425,"start":2426,"enrollment":2427,"conditions":2451,"interventions":2452},[89],[2429,781,2430],[2411,2432,2433,2434],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"intervention":2433,"totalTrials":94,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2471,"NA":2473},{"trials":2460,"activeCount":98},[],{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[2467],{"nctId":2422,"briefTitle":2423,"status":347,"phases":2468,"primaryCompletion":1596,"completion":2425,"start":2426,"enrollment":2427,"conditions":2469,"interventions":2470},[89],[2429,781,2430],[2411,2432,2433,2434],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[],{"intervention":2434,"totalTrials":94,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2483,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[2485],{"nctId":2422,"briefTitle":2423,"status":347,"phases":2486,"primaryCompletion":1596,"completion":2425,"start":2426,"enrollment":2427,"conditions":2487,"interventions":2488},[89],[2429,781,2430],[2411,2432,2433,2434],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"intervention":2494,"totalTrials":94,"cells":2495},"Semaglutide",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2502,"PHASE4":2514,"NA":2516},{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[],{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[2504],{"nctId":2505,"briefTitle":2506,"status":347,"phases":2507,"primaryCompletion":2508,"completion":2508,"start":2509,"enrollment":2510,"conditions":2511,"interventions":2513},"NCT04889183","SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes",[89],"2024-05-28","2022-03-14",125,[2512,357],"Obesity",[2494],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":98},[],{"intervention":2519,"totalTrials":94,"cells":2520},"Lanreotide",{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2539,"NA":2541},{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[2529],{"nctId":2530,"briefTitle":2531,"status":497,"phases":2532,"primaryCompletion":2533,"completion":2534,"start":2535,"enrollment":386,"conditions":2536,"interventions":2538},"NCT01616927","Study of Lanreotide to Treat Polycystic Kidney Disease",[89],"2017-08","2017-12","2012-06",[2537],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[2519],{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[],{"intervention":2346,"totalTrials":94,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":98},[],{"trials":2548,"activeCount":98},[],{"trials":2550,"activeCount":98},[],{"trials":2552,"activeCount":98},[2553],{"nctId":2338,"briefTitle":2339,"status":497,"phases":2554,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":2343,"conditions":2555,"interventions":2556},[89],[1584],[1586,2346],{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[],{"intervention":2562,"totalTrials":94,"cells":2563},"Abatacept SC",{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2568,"PHASE3":2570,"PHASE4":2582,"NA":2584},{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[2572],{"nctId":2573,"briefTitle":2574,"status":347,"phases":2575,"primaryCompletion":2576,"completion":2577,"start":2578,"enrollment":1508,"conditions":2579,"interventions":2581},"NCT02067910","Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome",[89],"2019-02","2019-08","2014-08",[2580],"Sjögren's Syndrome",[2562],{"trials":2583,"activeCount":98},[],{"trials":2585,"activeCount":98},[],{"intervention":2587,"totalTrials":94,"cells":2588},"Ferric carboxymaltose",{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2608,"NA":2610},{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[2597],{"nctId":2598,"briefTitle":2599,"status":347,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":255,"conditions":2603,"interventions":2606},"NCT03769441","Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation",[89],"2024-08-19","2019-08-02",[2604,2605],"Iron-deficiency","Transplant-Related Disorder",[2587,2607],"Sodium chloride",{"trials":2609,"activeCount":98},[],{"trials":2611,"activeCount":98},[],{"intervention":2607,"totalTrials":94,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2620,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":98},[],{"trials":2617,"activeCount":98},[],{"trials":2619,"activeCount":98},[],{"trials":2621,"activeCount":98},[2622],{"nctId":2598,"briefTitle":2599,"status":347,"phases":2623,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":255,"conditions":2624,"interventions":2625},[89],[2604,2605],[2587,2607],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[],{"intervention":2631,"totalTrials":94,"cells":2632},"Ambroxol Hydrochloride",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2651,"NA":2653},{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[2641],{"nctId":2642,"briefTitle":2643,"status":497,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":1508,"conditions":2647,"interventions":2650},"NCT05830396","GRoningen Early-PD Ambroxol Treatment",[88,89],"2025-07","2023-05",[2648,2649],"Parkinson","Parkinson Disease",[2631],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[],{"intervention":2656,"totalTrials":94,"cells":2657},"Spiromax Budesonide\u002Fformoterol",{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2664,"PHASE4":2677,"NA":2679},{"trials":2659,"activeCount":98},[],{"trials":2661,"activeCount":98},[],{"trials":2663,"activeCount":98},[],{"trials":2665,"activeCount":98},[2666],{"nctId":2667,"briefTitle":2668,"status":497,"phases":2669,"primaryCompletion":2670,"completion":2671,"start":2672,"enrollment":2673,"conditions":2674,"interventions":2675},"NCT02477397","Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD",[89],"2019-06-15","2019-12-15","2015-05-01",201,[24],[2656,2676],"Diskus Fluticasone\u002Fsalmeterol",{"trials":2678,"activeCount":98},[],{"trials":2680,"activeCount":98},[],{"intervention":2676,"totalTrials":94,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2695,"NA":2697},{"trials":2684,"activeCount":98},[],{"trials":2686,"activeCount":98},[],{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[2691],{"nctId":2667,"briefTitle":2668,"status":497,"phases":2692,"primaryCompletion":2670,"completion":2671,"start":2672,"enrollment":2673,"conditions":2693,"interventions":2694},[89],[24],[2656,2676],{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[],{"intervention":2700,"totalTrials":94,"cells":2701},"Sildenafil",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2708,"PHASE4":2721,"NA":2723},{"trials":2703,"activeCount":98},[],{"trials":2705,"activeCount":98},[],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[2710],{"nctId":2711,"briefTitle":2712,"status":347,"phases":2713,"primaryCompletion":2714,"completion":1595,"start":2715,"enrollment":2716,"conditions":2717,"interventions":2720},"NCT01726049","Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH",[89],"2014-09","2011-10",52,[2718,2719],"Heart Failure, Diastolic","Pulmonary Hypertension",[2700],{"trials":2722,"activeCount":98},[],{"trials":2724,"activeCount":98},[],{"intervention":2726,"totalTrials":94,"cells":2727},"low molecular weight heparin",{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2732,"PHASE3":2734,"PHASE4":2747,"NA":2749},{"trials":2729,"activeCount":98},[],{"trials":2731,"activeCount":98},[],{"trials":2733,"activeCount":98},[],{"trials":2735,"activeCount":98},[2736],{"nctId":2737,"briefTitle":2738,"status":608,"phases":2739,"primaryCompletion":2740,"completion":2740,"start":2741,"enrollment":1228,"conditions":2742,"interventions":2745},"NCT01164046","Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism",[89],"2014-07","2010-08",[2743,2744],"Venous Thromboembolism","Neoplasms",[2726,2746],"vitamin K antagonists",{"trials":2748,"activeCount":98},[],{"trials":2750,"activeCount":98},[],{"intervention":2746,"totalTrials":94,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2765,"NA":2767},{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"trials":2758,"activeCount":98},[],{"trials":2760,"activeCount":98},[2761],{"nctId":2737,"briefTitle":2738,"status":608,"phases":2762,"primaryCompletion":2740,"completion":2740,"start":2741,"enrollment":1228,"conditions":2763,"interventions":2764},[89],[2743,2744],[2726,2746],{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"intervention":2770,"totalTrials":94,"cells":2771},"Clarithromycin Extended Release",{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2778,"PHASE4":2790,"NA":2792},{"trials":2773,"activeCount":98},[],{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"trials":2779,"activeCount":98},[2780],{"nctId":2781,"briefTitle":2782,"status":347,"phases":2783,"primaryCompletion":2534,"completion":2192,"start":2784,"enrollment":2785,"conditions":2786,"interventions":2788},"NCT01659437","WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8",[88,89],"2012-12",310,[2787],"Mycobacterium Ulcerans Infection",[2770,2789],"Streptomycin intramuscular",{"trials":2791,"activeCount":98},[],{"trials":2793,"activeCount":98},[],{"intervention":2789,"totalTrials":94,"cells":2795},{"EARLY_PHASE1":2796,"PHASE1":2798,"PHASE2":2800,"PHASE3":2802,"PHASE4":2808,"NA":2810},{"trials":2797,"activeCount":98},[],{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[],{"trials":2803,"activeCount":98},[2804],{"nctId":2781,"briefTitle":2782,"status":347,"phases":2805,"primaryCompletion":2534,"completion":2192,"start":2784,"enrollment":2785,"conditions":2806,"interventions":2807},[88,89],[2787],[2770,2789],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"intervention":2813,"totalTrials":94,"cells":2814},"SR4 - switch to CR4",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2821,"PHASE4":2835,"NA":2837},{"trials":2816,"activeCount":98},[],{"trials":2818,"activeCount":98},[],{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[2823],{"nctId":2824,"briefTitle":2825,"status":347,"phases":2826,"primaryCompletion":2827,"completion":2828,"start":2829,"enrollment":2830,"conditions":2831,"interventions":2834},"NCT00321178","BURULICO Drug Trial Study Protocol: RCT SR8\u002FSR4+CR4, GHANA",[88,89],"2008-01","2009-02","2006-05",151,[2832,2833],"Buruli Ulcer","Mycobacterium Ulcerans",[2813],{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"intervention":2840,"totalTrials":94,"cells":2841},"QVM149",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2860,"NA":2862},{"trials":2843,"activeCount":98},[],{"trials":2845,"activeCount":98},[],{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[2850],{"nctId":2851,"briefTitle":2852,"status":347,"phases":2853,"primaryCompletion":2854,"completion":2854,"start":2855,"enrollment":552,"conditions":2856,"interventions":2858},"NCT04259164","Anti-inflammatory Effects Glycopyrronium",[89],"2022-12-29","2020-09-10",[34,2857],"Allergic Asthma",[2840,2859],"QMF149",{"trials":2861,"activeCount":98},[],{"trials":2863,"activeCount":98},[],{"intervention":2859,"totalTrials":94,"cells":2865},{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2878,"NA":2880},{"trials":2867,"activeCount":98},[],{"trials":2869,"activeCount":98},[],{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[2874],{"nctId":2851,"briefTitle":2852,"status":347,"phases":2875,"primaryCompletion":2854,"completion":2854,"start":2855,"enrollment":552,"conditions":2876,"interventions":2877},[89],[34,2857],[2840,2859],{"trials":2879,"activeCount":98},[],{"trials":2881,"activeCount":98},[],{"intervention":2883,"totalTrials":94,"cells":2884},"Heparin",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2891,"PHASE4":2907,"NA":2909},{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[2893],{"nctId":2894,"briefTitle":2895,"status":347,"phases":2896,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":2899,"conditions":2900,"interventions":2905},"NCT04536272","Reduced Anticoagulation Targets in ECLS (RATE)",[89],"2025-03-07","2020-10-01",330,[15,2901,2902,2903,2904],"Respiratory Failure","Extracorporeal Membrane Oxygenation","Bleeding","Thrombosis",[2883,2906],"LMWH",{"trials":2908,"activeCount":98},[],{"trials":2910,"activeCount":98},[],{"intervention":2906,"totalTrials":94,"cells":2912},{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2919,"PHASE4":2925,"NA":2927},{"trials":2914,"activeCount":98},[],{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":98},[2921],{"nctId":2894,"briefTitle":2895,"status":347,"phases":2922,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":2899,"conditions":2923,"interventions":2924},[89],[15,2901,2902,2903,2904],[2883,2906],{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"intervention":2930,"totalTrials":94,"cells":2931},"Brentuximab vedotin",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2949,"NA":2951},{"trials":2933,"activeCount":98},[],{"trials":2935,"activeCount":98},[],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":98},[2940],{"nctId":2941,"briefTitle":2942,"status":497,"phases":2943,"primaryCompletion":2944,"completion":573,"start":2945,"enrollment":155,"conditions":2946,"interventions":2948},"NCT06186986","CD30 Imaging in Diffuse Large B-cell Lymphoma",[89],"2025-01","2024-01",[2947],"Diffuse Large B-cell-lymphoma",[2930],{"trials":2950,"activeCount":98},[],{"trials":2952,"activeCount":98},[],{"intervention":2954,"totalTrials":27,"cells":2955},"Bevacizumab-IRDye800CW",{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":3033,"PHASE3":3063,"PHASE4":3065,"NA":3067},{"trials":2957,"activeCount":98},[],{"trials":2959,"activeCount":98},[2960,2968,2977,2986,2997,3005,3013,3024],{"nctId":2961,"briefTitle":2962,"status":347,"phases":2963,"primaryCompletion":1696,"completion":1696,"start":450,"enrollment":2964,"conditions":2965,"interventions":2967},"NCT02113202","Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW",[87],17,[2966],"Adenomatous Polyposis Coli",[2954],{"nctId":2969,"briefTitle":2970,"status":347,"phases":2971,"primaryCompletion":2972,"completion":2972,"start":1239,"enrollment":2973,"conditions":2974,"interventions":2976},"NCT02129933","VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions",[87],"2016-11",14,[26,2975],"Dysplasia",[2954],{"nctId":2978,"briefTitle":2979,"status":347,"phases":2980,"primaryCompletion":2981,"completion":2982,"start":2381,"enrollment":622,"conditions":2983,"interventions":2985},"NCT01972373","Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer",[87],"2016-12","2017-01",[2984],"Rectal Cancer",[2954],{"nctId":2987,"briefTitle":2988,"status":347,"phases":2989,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":22,"conditions":2993,"interventions":2996},"NCT05262244","Targeted Fluorescence Imaging in AMD",[87],"2023-03-30","2024-03-30","2022-10-28",[2994,2995],"Age-Related Macular Degeneration","NAMD",[2954],{"nctId":2998,"briefTitle":2999,"status":608,"phases":3000,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":1142,"conditions":3003,"interventions":3004},"NCT03558724","Fluorescence Endoscopy of Esophageal Carcinoma",[87],"2022-10-11","2018-10-29",[26],[2954],{"nctId":3006,"briefTitle":3007,"status":347,"phases":3008,"primaryCompletion":3009,"completion":2315,"start":2715,"enrollment":155,"conditions":3010,"interventions":3011},"NCT01508572","VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer",[87],"2014-11",[18],[3012],"bevacizumab-IRDye800CW",{"nctId":3014,"briefTitle":3015,"status":347,"phases":3016,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":155,"conditions":3019,"interventions":3023},"NCT04212793","Detection of PitNET Tissue During TSS Using Bevacizumab-800CW",[87],"2022-10-24","2020-10-28",[3020,3021,3022],"Pituitary Tumor","Pituitary Adenoma","Pituitary Macroadenoma",[2954],{"nctId":3025,"briefTitle":3026,"status":347,"phases":3027,"primaryCompletion":3028,"completion":3028,"start":3029,"enrollment":155,"conditions":3030,"interventions":3032},"NCT06095362","Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW",[87],"2023-10-12","2021-11-29",[1555,3031],"Surgery",[2954],{"trials":3034,"activeCount":98},[3035,3045,3054],{"nctId":3036,"briefTitle":3037,"status":347,"phases":3038,"primaryCompletion":3039,"completion":3040,"start":3041,"enrollment":19,"conditions":3042,"interventions":3044},"NCT03913806","FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW",[87,88],"2019-12-22","2020-01-01","2018-05-01",[3043],"Soft Tissue Sarcoma",[2954],{"nctId":3046,"briefTitle":3047,"status":497,"phases":3048,"primaryCompletion":3049,"completion":3049,"start":3050,"enrollment":22,"conditions":3051,"interventions":3053},"NCT03620292","Fluorescence Image Guided Surgery in Cholangiocarcinoma",[87,88],"2021-12-01","2019-04-01",[3052],"Hilar Cholangiocarcinoma",[2954],{"nctId":3055,"briefTitle":3056,"status":497,"phases":3057,"primaryCompletion":3058,"completion":3059,"start":111,"enrollment":539,"conditions":3060,"interventions":3062},"NCT03877601","Detection of Early Esophageal Cancer by NIR-FME.",[88],"2021-09-01","2021-10-01",[3061],"Barrett Esophagus",[2954],{"trials":3064,"activeCount":98},[],{"trials":3066,"activeCount":98},[],{"trials":3068,"activeCount":98},[],{"intervention":3070,"totalTrials":1483,"cells":3071},"Cetuximab-IRDye800",{"EARLY_PHASE1":3072,"PHASE1":3074,"PHASE2":3097,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3073,"activeCount":98},[],{"trials":3075,"activeCount":98},[3076,3088],{"nctId":3077,"briefTitle":3078,"status":497,"phases":3079,"primaryCompletion":3080,"completion":3081,"start":3082,"enrollment":3083,"conditions":3084,"interventions":3087},"NCT05929456","Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)",[87],"2024-10-01","2025-01-01","2023-05-05",21,[3085,3086],"Glioblastoma","High-grade Glioma",[3070],{"nctId":3089,"briefTitle":3090,"status":347,"phases":3091,"primaryCompletion":3092,"completion":3093,"start":3094,"enrollment":27,"conditions":3095,"interventions":3096},"NCT04638036","Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer",[87],"2022-01-28","2023-05-21","2020-11-13",[2984],[3070],{"trials":3098,"activeCount":98},[3099],{"nctId":3100,"briefTitle":3101,"status":347,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":3106,"conditions":3107,"interventions":3109},"NCT05499065","Real-time Margin Assessment in Head and Neck Cancer",[88],"2024-10-23","2025-01-10","2023-03-01",23,[3108,471],"Head and Neck Cancer",[3070],{"trials":3111,"activeCount":98},[],{"trials":3113,"activeCount":98},[],{"trials":3115,"activeCount":98},[],{"intervention":3117,"totalTrials":284,"cells":3118},"Tobramycin",{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3120,"activeCount":98},[],{"trials":3122,"activeCount":98},[],{"trials":3124,"activeCount":98},[3125,3134],{"nctId":3126,"briefTitle":3127,"status":497,"phases":3128,"primaryCompletion":3094,"completion":3129,"start":3130,"enrollment":30,"conditions":3131,"interventions":3133},"NCT03485456","DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis",[87,88],"2022-01-01","2019-05-29",[3132],"Cystic Fibrosis",[3117],{"nctId":3135,"briefTitle":3136,"status":347,"phases":3137,"primaryCompletion":1595,"completion":1595,"start":2381,"enrollment":3138,"conditions":3139,"interventions":3141},"NCT02035488","Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis",[87,88],8,[3140],"Bronchiectasis",[3117],{"trials":3143,"activeCount":98},[],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"intervention":3149,"totalTrials":284,"cells":3150},"Vvax001 therapeutic cancer vaccine",{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3165,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3152,"activeCount":98},[],{"trials":3154,"activeCount":98},[3155],{"nctId":3156,"briefTitle":3157,"status":347,"phases":3158,"primaryCompletion":3159,"completion":3159,"start":3160,"enrollment":22,"conditions":3161,"interventions":3164},"NCT03141463","Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions",[87],"2017-11-28","2017-01-13",[3162,3163],"CIN 2\u002F3","Cervical Cancer",[3149],{"trials":3166,"activeCount":98},[3167],{"nctId":3168,"briefTitle":3169,"status":497,"phases":3170,"primaryCompletion":3171,"completion":179,"start":3172,"enrollment":16,"conditions":3173,"interventions":3178},"NCT06015854","Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II",[88],"2024-02-06","2021-03-23",[3174,3175,3176,3177],"CIN3","Cervical Intraepithelial Neoplasia","Cervical Intraepithelial Neoplasia Grade 3","HPV 16 Infection",[3149],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"intervention":3186,"totalTrials":284,"cells":3187},"Cetuximab-IRDye800CW",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3203,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3189,"activeCount":98},[],{"trials":3191,"activeCount":98},[3192],{"nctId":3193,"briefTitle":3194,"status":347,"phases":3195,"primaryCompletion":3196,"completion":3197,"start":3198,"enrollment":27,"conditions":3199,"interventions":3202},"NCT05376202","Image Guided Penile Cancer Surgery",[87],"2023-05-01","2024-04-14","2022-03-07",[3200,3201],"Penile Cancer","Margin Assessment",[3186],{"trials":3204,"activeCount":98},[3205],{"nctId":3206,"briefTitle":3207,"status":497,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3214},"NCT03134846","Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate",[87,88],"2021-12","2022-06","2017-12-16",79,[471,3201],[3186],{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"intervention":3222,"totalTrials":94,"cells":3223},"Midostaurin,",{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":98},[],{"trials":3229,"activeCount":98},[3230],{"nctId":3231,"briefTitle":3232,"status":497,"phases":3233,"primaryCompletion":3234,"completion":3235,"start":3236,"enrollment":155,"conditions":3237,"interventions":3239},"NCT01920204","Midostaurin in Indolent Systemic Mastocytosis",[88],"2015-03","2015-05","2013-08",[3238],"Indolent Systemic Mastocytosis",[3222],{"trials":3241,"activeCount":98},[],{"trials":3243,"activeCount":98},[],{"trials":3245,"activeCount":98},[],{"intervention":3247,"totalTrials":94,"cells":3248},"ertapenem",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3264,"PHASE4":3266,"NA":3268},{"trials":3250,"activeCount":98},[],{"trials":3252,"activeCount":98},[],{"trials":3254,"activeCount":98},[3255],{"nctId":3256,"briefTitle":3257,"status":347,"phases":3258,"primaryCompletion":3259,"completion":3259,"start":3260,"enrollment":22,"conditions":3261,"interventions":3263},"NCT01730664","PK\u002FPD of Ertapenem In Patients With TB",[88],"2017-07-13","2017-01-26",[3262],"PK of Ertapenem in TB Patients",[3247],{"trials":3265,"activeCount":98},[],{"trials":3267,"activeCount":98},[],{"trials":3269,"activeCount":98},[],{"intervention":3271,"totalTrials":94,"cells":3272},"epoetin alfa",{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3289,"PHASE4":3291,"NA":3293},{"trials":3274,"activeCount":98},[],{"trials":3276,"activeCount":98},[],{"trials":3278,"activeCount":98},[3279],{"nctId":3280,"briefTitle":3281,"status":347,"phases":3282,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":3285,"conditions":3286,"interventions":3288},"NCT00449488","Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction",[88],"2009-10","2007-01",529,[3287],"Myocardial Infarction",[3271],{"trials":3290,"activeCount":98},[],{"trials":3292,"activeCount":98},[],{"trials":3294,"activeCount":98},[],{"intervention":3296,"totalTrials":94,"cells":3297},"Anifrolumab",{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3302,"PHASE3":3313,"PHASE4":3315,"NA":3317},{"trials":3299,"activeCount":98},[],{"trials":3301,"activeCount":98},[],{"trials":3303,"activeCount":98},[3304],{"nctId":3305,"briefTitle":3306,"status":497,"phases":3307,"primaryCompletion":1481,"completion":3308,"start":3309,"enrollment":622,"conditions":3310,"interventions":3312},"NCT05383677","Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome",[88],"2024-08-01","2022-10-01",[3311],"Sjogren's Syndrome",[3296],{"trials":3314,"activeCount":98},[],{"trials":3316,"activeCount":98},[],{"trials":3318,"activeCount":98},[],{"intervention":3320,"totalTrials":94,"cells":3321},"Heme arginate",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":98},[3328],{"nctId":3329,"briefTitle":3330,"status":347,"phases":3331,"primaryCompletion":3332,"completion":3332,"start":3333,"enrollment":1264,"conditions":3334,"interventions":3336},"NCT00483587","Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?",[87,88],"2010-02","2007-07",[3335],"Acute Myocardial Infarction",[3320],{"trials":3338,"activeCount":98},[],{"trials":3340,"activeCount":98},[],{"trials":3342,"activeCount":98},[],{"intervention":3344,"totalTrials":94,"cells":3345},"MPDL3280A",{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3363,"PHASE4":3365,"NA":3367},{"trials":3347,"activeCount":98},[],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[3352],{"nctId":3353,"briefTitle":3354,"status":497,"phases":3355,"primaryCompletion":3356,"completion":3357,"start":3358,"enrollment":3359,"conditions":3360,"interventions":3362},"NCT02478099","MPDL3280A-treatment-IST-UMCG",[88],"2023-09-19","2024-07","2016-02-24",81,[3361],"Locally Advanced or Metastatic Solid Tumors",[3344],{"trials":3364,"activeCount":98},[],{"trials":3366,"activeCount":98},[],{"trials":3368,"activeCount":98},[],{"intervention":3370,"totalTrials":94,"cells":3371},"GC1008",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":98},[],{"trials":3377,"activeCount":98},[3378],{"nctId":3379,"briefTitle":3380,"status":347,"phases":3381,"primaryCompletion":2168,"completion":2168,"start":2118,"enrollment":22,"conditions":3382,"interventions":3384},"NCT01472731","Safety and Imaging Study of GC1008 in Glioma",[88],[3383],"Primary Brain Tumors",[3370],{"trials":3386,"activeCount":98},[],{"trials":3388,"activeCount":98},[],{"trials":3390,"activeCount":98},[],{"intervention":3392,"totalTrials":94,"cells":3393},"rituximab",{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3407,"PHASE4":3409,"NA":3411},{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[3400],{"nctId":3401,"briefTitle":3402,"status":347,"phases":3403,"primaryCompletion":2299,"completion":2299,"start":3404,"enrollment":622,"conditions":3405,"interventions":3406},"NCT00363350","Rituximab Treatment in Sjogren's Syndrome",[87,88],"2006-08",[3311],[3392],{"trials":3408,"activeCount":98},[],{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[],{"intervention":3414,"totalTrials":94,"cells":3415},"Apomorphine 0.25%",{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[3422],{"nctId":3423,"briefTitle":3424,"status":608,"phases":3425,"primaryCompletion":3426,"completion":3426,"start":1866,"enrollment":3427,"conditions":3428,"interventions":3431},"NCT02230930","Treatment of Apomorphine-induced Skin Reactions: a Pilot Study",[88],"2018-12-31",13,[3429,3430],"Parkinson's Disease","Apomorphine-induced Skin Reactions",[3414,3432,3433],"Hydrocortisone cream 1%","Subcutaneous hydrocortisone 10mg",{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[],{"trials":3439,"activeCount":98},[],{"intervention":3432,"totalTrials":94,"cells":3441},{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3446,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":98},[3448],{"nctId":3423,"briefTitle":3424,"status":608,"phases":3449,"primaryCompletion":3426,"completion":3426,"start":1866,"enrollment":3427,"conditions":3450,"interventions":3451},[88],[3429,3430],[3414,3432,3433],{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[],{"intervention":3433,"totalTrials":94,"cells":3459},{"EARLY_PHASE1":3460,"PHASE1":3462,"PHASE2":3464,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3461,"activeCount":98},[],{"trials":3463,"activeCount":98},[],{"trials":3465,"activeCount":98},[3466],{"nctId":3423,"briefTitle":3424,"status":608,"phases":3467,"primaryCompletion":3426,"completion":3426,"start":1866,"enrollment":3427,"conditions":3468,"interventions":3469},[88],[3429,3430],[3414,3432,3433],{"trials":3471,"activeCount":98},[],{"trials":3473,"activeCount":98},[],{"trials":3475,"activeCount":98},[],{"intervention":3477,"totalTrials":94,"cells":3478},"89Zr-trastuzumab",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3493,"PHASE4":3495,"NA":3497},{"trials":3480,"activeCount":98},[],{"trials":3482,"activeCount":98},[],{"trials":3484,"activeCount":98},[3485],{"nctId":3486,"briefTitle":3487,"status":347,"phases":3488,"primaryCompletion":1866,"completion":1696,"start":3489,"enrollment":155,"conditions":3490,"interventions":3492},"NCT01832051","Clinical Value of 89Zr-trastuzumab PET",[88],"2013-03",[3491],"Metastatic Breast Cancer",[3477],{"trials":3494,"activeCount":98},[],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"intervention":3500,"totalTrials":94,"cells":3501},"AKS-452X",{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3519,"PHASE4":3521,"NA":3523},{"trials":3503,"activeCount":98},[],{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[3508],{"nctId":3509,"briefTitle":3510,"status":497,"phases":3511,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3516,"interventions":3518},"NCT05124483","Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)",[88],"2022-07-01","2023-02-01","2022-04-21",600,[3517],"COVID-19",[3500],{"trials":3520,"activeCount":98},[],{"trials":3522,"activeCount":98},[],{"trials":3524,"activeCount":98},[],{"intervention":588,"totalTrials":94,"cells":3526},{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[],{"trials":3532,"activeCount":98},[3533],{"nctId":580,"briefTitle":581,"status":347,"phases":3534,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":3535,"interventions":3536},[88],[182],[588,560,589],{"trials":3538,"activeCount":98},[],{"trials":3540,"activeCount":98},[],{"trials":3542,"activeCount":98},[],{"intervention":589,"totalTrials":94,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3546,"activeCount":98},[],{"trials":3548,"activeCount":98},[],{"trials":3550,"activeCount":98},[3551],{"nctId":580,"briefTitle":581,"status":347,"phases":3552,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":3553,"interventions":3554},[88],[182],[588,560,589],{"trials":3556,"activeCount":98},[],{"trials":3558,"activeCount":98},[],{"trials":3560,"activeCount":98},[],{"intervention":3562,"totalTrials":94,"cells":3563},"Beriplex",{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3568,"PHASE3":3578,"PHASE4":3580,"NA":3582},{"trials":3565,"activeCount":98},[],{"trials":3567,"activeCount":98},[],{"trials":3569,"activeCount":98},[3570],{"nctId":3571,"briefTitle":3572,"status":497,"phases":3573,"primaryCompletion":3574,"completion":2981,"start":2315,"enrollment":22,"conditions":3575,"interventions":3577},"NCT02463591","Reversal of Dabigatran With Prothrombin Complex Concentrate",[88],"2016-07",[3576],"Drug Action Reversal",[3562],{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"intervention":3585,"totalTrials":94,"cells":3586},"Apomorphine",{"EARLY_PHASE1":3587,"PHASE1":3589,"PHASE2":3591,"PHASE3":3602,"PHASE4":3604,"NA":3606},{"trials":3588,"activeCount":98},[],{"trials":3590,"activeCount":98},[],{"trials":3592,"activeCount":98},[3593],{"nctId":3594,"briefTitle":3595,"status":497,"phases":3596,"primaryCompletion":2534,"completion":2534,"start":3597,"enrollment":3598,"conditions":3599,"interventions":3601},"NCT02702076","Apomorphine in Parkinson's Disease Patients With Visual Hallucinations",[88],"2017-05",35,[3429,3600],"Hallucinations, Visual",[3585],{"trials":3603,"activeCount":98},[],{"trials":3605,"activeCount":98},[],{"trials":3607,"activeCount":98},[],{"intervention":3609,"totalTrials":94,"cells":3610},"Sodium Thiosulfate Pentahydrate",{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[3617],{"nctId":3618,"briefTitle":3619,"status":347,"phases":3620,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":16,"conditions":3623,"interventions":3625},"NCT03017963","Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach.",[87,88],"2018-03-23","2017-10-06",[3624],"Acute Coronary Syndrome",[3609],{"trials":3627,"activeCount":98},[],{"trials":3629,"activeCount":98},[],{"trials":3631,"activeCount":98},[],{"intervention":3633,"totalTrials":94,"cells":3634},"Bicalutamide",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3649,"PHASE4":3651,"NA":3653},{"trials":3636,"activeCount":98},[],{"trials":3638,"activeCount":98},[],{"trials":3640,"activeCount":98},[3641],{"nctId":3642,"briefTitle":3643,"status":347,"phases":3644,"primaryCompletion":3645,"completion":3645,"start":468,"enrollment":3646,"conditions":3647,"interventions":3648},"NCT02697032","FDHT PET and Bicalutamide in Metastatic Breast Cancer",[88],"2019-11-25",22,[18],[3633],{"trials":3650,"activeCount":98},[],{"trials":3652,"activeCount":98},[],{"trials":3654,"activeCount":98},[],{"intervention":2304,"totalTrials":94,"cells":3656},{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3667,"PHASE4":3669,"NA":3671},{"trials":3658,"activeCount":98},[],{"trials":3660,"activeCount":98},[],{"trials":3662,"activeCount":98},[3663],{"nctId":2295,"briefTitle":2296,"status":347,"phases":3664,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":2300,"conditions":3665,"interventions":3666},[88],[2302],[2304,530],{"trials":3668,"activeCount":98},[],{"trials":3670,"activeCount":98},[],{"trials":3672,"activeCount":98},[],{"intervention":1541,"totalTrials":94,"cells":3674},{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3685,"PHASE4":3687,"NA":3689},{"trials":3676,"activeCount":98},[],{"trials":3678,"activeCount":98},[],{"trials":3680,"activeCount":98},[3681],{"nctId":1534,"briefTitle":1535,"status":347,"phases":3682,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":622,"conditions":3683,"interventions":3684},[88],[18],[1525,1541],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"trials":3690,"activeCount":98},[],{"intervention":3692,"totalTrials":94,"cells":3693},"cyclosporine",{"EARLY_PHASE1":3694,"PHASE1":3696,"PHASE2":3698,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3695,"activeCount":98},[],{"trials":3697,"activeCount":98},[],{"trials":3699,"activeCount":98},[3700],{"nctId":3701,"briefTitle":3702,"status":497,"phases":3703,"start":3704,"enrollment":1142,"conditions":3705,"interventions":3707},"NCT00002688","Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88],"1995-02",[3706],"Leukemia",[3692,3708,3709],"etoposide","mitoxantrone hydrochloride",{"trials":3711,"activeCount":98},[],{"trials":3713,"activeCount":98},[],{"trials":3715,"activeCount":98},[],{"intervention":3708,"totalTrials":94,"cells":3717},{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3719,"activeCount":98},[],{"trials":3721,"activeCount":98},[],{"trials":3723,"activeCount":98},[3724],{"nctId":3701,"briefTitle":3702,"status":497,"phases":3725,"start":3704,"enrollment":1142,"conditions":3726,"interventions":3727},[88],[3706],[3692,3708,3709],{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[],{"trials":3733,"activeCount":98},[],{"intervention":3709,"totalTrials":94,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[],{"trials":3741,"activeCount":98},[3742],{"nctId":3701,"briefTitle":3702,"status":497,"phases":3743,"start":3704,"enrollment":1142,"conditions":3744,"interventions":3745},[88],[3706],[3692,3708,3709],{"trials":3747,"activeCount":98},[],{"trials":3749,"activeCount":98},[],{"trials":3751,"activeCount":98},[],{"intervention":529,"totalTrials":94,"cells":3753},{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3764,"PHASE4":3766,"NA":3768},{"trials":3755,"activeCount":98},[],{"trials":3757,"activeCount":98},[],{"trials":3759,"activeCount":98},[3760],{"nctId":520,"briefTitle":521,"status":347,"phases":3761,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":3762,"interventions":3763},[88],[527],[529,530,487],{"trials":3765,"activeCount":98},[],{"trials":3767,"activeCount":98},[],{"trials":3769,"activeCount":98},[],{"intervention":3771,"totalTrials":94,"cells":3772},"Adalimumab-680LT",{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3774,"activeCount":98},[],{"trials":3776,"activeCount":98},[],{"trials":3778,"activeCount":98},[3779],{"nctId":3780,"briefTitle":3781,"status":497,"phases":3782,"primaryCompletion":3783,"completion":44,"start":3784,"enrollment":3083,"conditions":3785,"interventions":3787},"NCT06117423","Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease",[87,88],"2024-12","2024-03",[258,3786],"Ulcerative Colitis",[3771],{"trials":3789,"activeCount":98},[],{"trials":3791,"activeCount":98},[],{"trials":3793,"activeCount":98},[],{"intervention":3795,"totalTrials":94,"cells":3796},"Guselkumab",{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3798,"activeCount":98},[],{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[3803],{"nctId":3804,"briefTitle":3805,"status":347,"phases":3806,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":155,"conditions":3810,"interventions":3811},"NCT04061395","Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.",[88],"2021-12-30","2022-04-01","2019-10-01",[1242],[3795],{"trials":3813,"activeCount":98},[],{"trials":3815,"activeCount":98},[],{"trials":3817,"activeCount":98},[],{"intervention":456,"totalTrials":94,"cells":3819},{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3821,"activeCount":98},[],{"trials":3823,"activeCount":98},[],{"trials":3825,"activeCount":98},[3826],{"nctId":447,"briefTitle":448,"status":347,"phases":3827,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":3828,"interventions":3829},[87,88],[454],[456,423],{"trials":3831,"activeCount":98},[],{"trials":3833,"activeCount":98},[],{"trials":3835,"activeCount":98},[],{"intervention":3837,"totalTrials":94,"cells":3838},"Aliskiren",{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3840,"activeCount":98},[],{"trials":3842,"activeCount":98},[],{"trials":3844,"activeCount":98},[3845],{"nctId":3846,"briefTitle":3847,"status":608,"phases":3848,"primaryCompletion":3849,"completion":2784,"start":3850,"enrollment":1092,"conditions":3851,"interventions":3852},"NCT00881439","Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment",[88],"2012-07","2009-04",[15,415],[3837],{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[],{"trials":3858,"activeCount":98},[],{"intervention":3860,"totalTrials":94,"cells":3861},"AKS-452",{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3877,"PHASE4":3879,"NA":3881},{"trials":3863,"activeCount":98},[],{"trials":3865,"activeCount":98},[],{"trials":3867,"activeCount":98},[3868],{"nctId":3869,"briefTitle":3870,"status":347,"phases":3871,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":3874,"conditions":3875,"interventions":3876},"NCT04681092","Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study",[87,88],"2022-03-10","2021-04-06",112,[2075],[3860],{"trials":3878,"activeCount":98},[],{"trials":3880,"activeCount":98},[],{"trials":3882,"activeCount":98},[],{"intervention":3884,"totalTrials":94,"cells":3885},"Veliparib",{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3887,"activeCount":98},[],{"trials":3889,"activeCount":98},[],{"trials":3891,"activeCount":98},[3892],{"nctId":3893,"briefTitle":3894,"status":3895,"phases":3896,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":98,"conditions":3899,"interventions":3900},"NCT03044795","Response to PARP Inhibitor Predicted by the RAD51 Assay","WITHDRAWN",[88],"2020-11","2019-11",[32],[3884],{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"intervention":3908,"totalTrials":94,"cells":3909},"Chemotherapy",{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[3916],{"nctId":3917,"briefTitle":3918,"status":608,"phases":3919,"start":3920,"enrollment":3921,"conditions":3922,"interventions":3924},"NCT00851110","Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors",[88],"2004-10",50,[3923],"High-Risk Breast Cancer",[3908],{"trials":3926,"activeCount":98},[],{"trials":3928,"activeCount":98},[],{"trials":3930,"activeCount":98},[],{"intervention":3932,"totalTrials":94,"cells":3933},"[6,6-2H2]glucose",{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3938,"PHASE3":3949,"PHASE4":3951,"NA":3953},{"trials":3935,"activeCount":98},[],{"trials":3937,"activeCount":98},[],{"trials":3939,"activeCount":98},[3940],{"nctId":3941,"briefTitle":3942,"status":347,"phases":3943,"primaryCompletion":3944,"completion":3944,"start":3945,"enrollment":155,"conditions":3946,"interventions":3948},"NCT04311307","Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia",[87,88],"2022-02-07","2021-01-19",[3947],"Glycogen Storage Disease Type IA",[3932],{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[],{"intervention":3956,"totalTrials":94,"cells":3957},"Sodium thiosulfate",{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":3974,"PHASE4":3976,"NA":3978},{"trials":3959,"activeCount":98},[],{"trials":3961,"activeCount":98},[],{"trials":3963,"activeCount":98},[3964],{"nctId":3965,"briefTitle":3966,"status":497,"phases":3967,"primaryCompletion":3968,"completion":3969,"start":3970,"enrollment":2383,"conditions":3971,"interventions":3972},"NCT02899364","Sodium Thiosulfate to Preserve Cardiac Function in STEMI",[88],"2021-06-25","2023-03","2018-07-20",[3287,15],[3956,3973],"Sodium chloride 0.9%",{"trials":3975,"activeCount":98},[],{"trials":3977,"activeCount":98},[],{"trials":3979,"activeCount":98},[],{"intervention":3973,"totalTrials":94,"cells":3981},{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3986,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3983,"activeCount":98},[],{"trials":3985,"activeCount":98},[],{"trials":3987,"activeCount":98},[3988],{"nctId":3965,"briefTitle":3966,"status":497,"phases":3989,"primaryCompletion":3968,"completion":3969,"start":3970,"enrollment":2383,"conditions":3990,"interventions":3991},[88],[3287,15],[3956,3973],{"trials":3993,"activeCount":98},[],{"trials":3995,"activeCount":98},[],{"trials":3997,"activeCount":98},[],{"intervention":3999,"totalTrials":94,"cells":4000},"co-trimoxazole",{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4013,"PHASE4":4015,"NA":4017},{"trials":4002,"activeCount":98},[],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[4007],{"nctId":4008,"briefTitle":4009,"status":347,"phases":4010,"primaryCompletion":2578,"completion":2578,"start":2381,"enrollment":22,"conditions":4011,"interventions":4012},"NCT01832987","Pharmacokinetic Parameters of Co-trimoxazole",[88],[1869],[3999],{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[],{"trials":4018,"activeCount":98},[],{"intervention":4020,"totalTrials":94,"cells":4021},"intravenous administration of 1st line TB drugs, day 1",{"EARLY_PHASE1":4022,"PHASE1":4024,"PHASE2":4026,"PHASE3":4034,"PHASE4":4036,"NA":4038},{"trials":4023,"activeCount":98},[],{"trials":4025,"activeCount":98},[],{"trials":4027,"activeCount":98},[4028],{"nctId":4029,"briefTitle":4030,"status":347,"phases":4031,"primaryCompletion":1239,"completion":1594,"start":523,"enrollment":155,"conditions":4032,"interventions":4033},"NCT02121314","HRZE Fasted\u002FFed in Newly Diagnosed TB",[88],[1869],[4020],{"trials":4035,"activeCount":98},[],{"trials":4037,"activeCount":98},[],{"trials":4039,"activeCount":98},[],{"intervention":4041,"totalTrials":94,"cells":4042},"NaCl 0.9%",{"EARLY_PHASE1":4043,"PHASE1":4045,"PHASE2":4047,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4044,"activeCount":98},[],{"trials":4046,"activeCount":98},[],{"trials":4048,"activeCount":98},[4049],{"nctId":4050,"briefTitle":4051,"status":347,"phases":4052,"primaryCompletion":2382,"completion":1950,"start":4053,"enrollment":30,"conditions":4054,"interventions":4056},"NCT00524901","Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia",[88],"2007-09",[4055,2386],"CABG",[4057,4041],"Epoetin alpha",{"trials":4059,"activeCount":98},[],{"trials":4061,"activeCount":98},[],{"trials":4063,"activeCount":98},[],{"intervention":4065,"totalTrials":94,"cells":4066},"Azithromycin 250 mg",{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4082,"PHASE4":4084,"NA":4086},{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":98},[4073],{"nctId":4074,"briefTitle":4075,"status":347,"phases":4076,"primaryCompletion":4077,"completion":4077,"start":4078,"enrollment":501,"conditions":4079,"interventions":4081},"NCT03160638","Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis",[88],"2022-05-22","2018-02-01",[4080],"Tuberculosis, Pulmonary",[4065],{"trials":4083,"activeCount":98},[],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[],{"intervention":4089,"totalTrials":94,"cells":4090},"Dupilumab",{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4105,"PHASE4":4107,"NA":4109},{"trials":4092,"activeCount":98},[],{"trials":4094,"activeCount":98},[],{"trials":4096,"activeCount":98},[4097],{"nctId":4098,"briefTitle":4099,"status":497,"phases":4100,"primaryCompletion":4101,"completion":4101,"start":4102,"enrollment":622,"conditions":4103,"interventions":4104},"NCT04512339","Dupilumab in Severe Chronic Hand Eczema",[88],"2022-08","2020-08-01",[1584],[4089],{"trials":4106,"activeCount":98},[],{"trials":4108,"activeCount":98},[],{"trials":4110,"activeCount":98},[],{"intervention":4112,"totalTrials":94,"cells":4113},"Valaciclovir",{"EARLY_PHASE1":4114,"PHASE1":4116,"PHASE2":4118,"PHASE3":4129,"PHASE4":4131,"NA":4133},{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[],{"trials":4119,"activeCount":98},[4120],{"nctId":4121,"briefTitle":4122,"status":347,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":1950,"enrollment":501,"conditions":4125,"interventions":4128},"NCT01364792","To Rescue Cognition With Valaciclovir",[88],"2015-08",[4126,4127],"Schizophrenia","Psychosis",[4112],{"trials":4130,"activeCount":98},[],{"trials":4132,"activeCount":98},[],{"trials":4134,"activeCount":98},[],{"intervention":4136,"totalTrials":94,"cells":4137},"Vitamin D",{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[],{"trials":4143,"activeCount":98},[4144],{"nctId":4145,"briefTitle":4146,"status":347,"phases":4147,"primaryCompletion":4148,"completion":4149,"start":451,"enrollment":4150,"conditions":4151,"interventions":4153},"NCT01092130","Study to Investigate the Effects of Vitamin D Administration on Plasma Renin Activity in Patients With Stable Chronic Heart Failure",[88],"2012-03","2012-09",101,[4152],"Chronic Heart Failure",[4136],{"trials":4155,"activeCount":98},[],{"trials":4157,"activeCount":98},[],{"trials":4159,"activeCount":98},[],{"intervention":505,"totalTrials":284,"cells":4161},{"EARLY_PHASE1":4162,"PHASE1":4172,"PHASE2":4178,"PHASE3":4180,"PHASE4":4182,"NA":4184},{"trials":4163,"activeCount":98},[4164],{"nctId":4165,"briefTitle":4166,"status":497,"phases":4167,"primaryCompletion":4168,"completion":3105,"start":4169,"enrollment":22,"conditions":4170,"interventions":4171},"NCT05639127","The Treatment of Adrenal Crisis With Inhaled Prednisolone",[86],"2022-11-30","2022-11-03",[1777],[505],{"trials":4173,"activeCount":98},[4174],{"nctId":495,"briefTitle":496,"status":497,"phases":4175,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":4176,"interventions":4177},[87],[503],[505,487],{"trials":4179,"activeCount":98},[],{"trials":4181,"activeCount":98},[],{"trials":4183,"activeCount":98},[],{"trials":4185,"activeCount":98},[],{"intervention":4187,"totalTrials":94,"cells":4188},"Pembrolizumab",{"EARLY_PHASE1":4189,"PHASE1":4191,"PHASE2":4203,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4190,"activeCount":98},[],{"trials":4192,"activeCount":98},[4193],{"nctId":4194,"briefTitle":4195,"status":347,"phases":4196,"primaryCompletion":4197,"completion":4198,"start":4199,"enrollment":30,"conditions":4200,"interventions":4202},"NCT04262089","Neo-adjuvant Pembrolizumab in dMMR\u002F POLE-EDM Uterine Cancer Patients: a Feasibility Study",[87],"2023-04-17","2023-11-01","2020-11-01",[4201],"Uterine Cancer",[4187],{"trials":4204,"activeCount":98},[],{"trials":4206,"activeCount":98},[],{"trials":4208,"activeCount":98},[],{"trials":4210,"activeCount":98},[],{"intervention":4212,"totalTrials":94,"cells":4213},"inhaled hydroxychloroquine",{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4215,"activeCount":98},[],{"trials":4217,"activeCount":98},[4218],{"nctId":4219,"briefTitle":4220,"status":347,"phases":4221,"primaryCompletion":4222,"completion":4199,"start":4223,"enrollment":22,"conditions":4224,"interventions":4225},"NCT04497519","Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers",[87],"2020-10-15","2020-09-15",[2075],[4212],{"trials":4227,"activeCount":98},[],{"trials":4229,"activeCount":98},[],{"trials":4231,"activeCount":98},[],{"trials":4233,"activeCount":98},[],{"intervention":4235,"totalTrials":94,"cells":4236},"89Zr-AMG211",{"EARLY_PHASE1":4237,"PHASE1":4239,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4238,"activeCount":98},[],{"trials":4240,"activeCount":98},[4241],{"nctId":4242,"briefTitle":4243,"status":347,"phases":4244,"primaryCompletion":4245,"completion":4245,"start":611,"enrollment":452,"conditions":4246,"interventions":4248},"NCT02760199","89Zr-AMG211 PET Imaging Study",[87],"2017-05-03",[4247],"Advanced Gastrointestinal Cancer",[4235],{"trials":4250,"activeCount":98},[],{"trials":4252,"activeCount":98},[],{"trials":4254,"activeCount":98},[],{"trials":4256,"activeCount":98},[],{"intervention":4258,"totalTrials":94,"cells":4259},"W_ova1 Vaccine",{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4271,"PHASE3":4273,"PHASE4":4275,"NA":4277},{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[4264],{"nctId":4265,"briefTitle":4266,"status":608,"phases":4267,"primaryCompletion":4268,"completion":4268,"start":3645,"enrollment":3138,"conditions":4269,"interventions":4270},"NCT04163094","Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy",[87],"2023-06-26",[2302],[4258],{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":98},[],{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"intervention":4280,"totalTrials":94,"cells":4281},"Fluorescence endoscopy using durvalumab-680LT",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4295,"PHASE3":4297,"PHASE4":4299,"NA":4301},{"trials":4283,"activeCount":98},[],{"trials":4285,"activeCount":98},[4286],{"nctId":4287,"briefTitle":4288,"status":347,"phases":4289,"primaryCompletion":4290,"completion":4291,"start":4292,"enrollment":3083,"conditions":4293,"interventions":4294},"NCT05450484","Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer",[87],"2024-11-25","2024-12-01","2023-04-05",[26],[4280],{"trials":4296,"activeCount":98},[],{"trials":4298,"activeCount":98},[],{"trials":4300,"activeCount":98},[],{"trials":4302,"activeCount":98},[],{"intervention":4304,"totalTrials":94,"cells":4305},"IV-administation of EMI-137",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4320,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4307,"activeCount":98},[],{"trials":4309,"activeCount":98},[4310],{"nctId":4311,"briefTitle":4312,"status":347,"phases":4313,"primaryCompletion":4314,"completion":4315,"start":4316,"enrollment":1264,"conditions":4317,"interventions":4319},"NCT03205501","Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions",[87],"2019-03-25","2019-09-01","2017-02-09",[3061,26,4318],"Dysplasia in Barrett Esophagus",[4304],{"trials":4321,"activeCount":98},[],{"trials":4323,"activeCount":98},[],{"trials":4325,"activeCount":98},[],{"trials":4327,"activeCount":98},[],{"intervention":4329,"totalTrials":94,"cells":4330},"89Zr-MMOT0530A",{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4349,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4332,"activeCount":98},[],{"trials":4334,"activeCount":98},[4335],{"nctId":4336,"briefTitle":4337,"status":347,"phases":4338,"primaryCompletion":4339,"completion":4339,"start":3489,"enrollment":27,"conditions":4340,"interventions":4348},"NCT01832116","89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients",[87],"2014-05",[4341,4342,4343,4344,4345,4346,4347],"Ovarian Neoplasms","Ovarian Diseases","Adnexal Diseases","Pancreatic Neoplasms","Digestive System Neoplasms","Digestive System Diseases","Pancreatic Diseases",[4329],{"trials":4350,"activeCount":98},[],{"trials":4352,"activeCount":98},[],{"trials":4354,"activeCount":98},[],{"trials":4356,"activeCount":98},[],{"intervention":4358,"totalTrials":94,"cells":4359},"IV adminstration of EMI-137",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4373,"PHASE3":4375,"PHASE4":4377,"NA":4379},{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[4364],{"nctId":4365,"briefTitle":4366,"status":347,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":2300,"conditions":4370,"interventions":4372},"NCT03470259","Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging",[87],"2019-12-31","2018-06-20",[4371,443],"Papillary Thyroid Cancer",[4358],{"trials":4374,"activeCount":98},[],{"trials":4376,"activeCount":98},[],{"trials":4378,"activeCount":98},[],{"trials":4380,"activeCount":98},[],{"intervention":2372,"totalTrials":94,"cells":4382},{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4397},{"trials":4384,"activeCount":98},[],{"trials":4386,"activeCount":98},[4387],{"nctId":2363,"briefTitle":2364,"status":347,"phases":4388,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":1264,"conditions":4389,"interventions":4390},[87],[2369],[2356,2371,2372],{"trials":4392,"activeCount":98},[],{"trials":4394,"activeCount":98},[],{"trials":4396,"activeCount":98},[],{"trials":4398,"activeCount":98},[],{"intervention":4400,"totalTrials":94,"cells":4401},"Fluorescence molecular imaging procedure using vedolizumab-800CW",{"EARLY_PHASE1":4402,"PHASE1":4404,"PHASE2":4416,"PHASE3":4418,"PHASE4":4420,"NA":4422},{"trials":4403,"activeCount":98},[],{"trials":4405,"activeCount":98},[4406],{"nctId":4407,"briefTitle":4408,"status":347,"phases":4409,"primaryCompletion":3309,"completion":4410,"start":4411,"enrollment":4412,"conditions":4413,"interventions":4414},"NCT04112212","Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients",[87],"2023-01-01","2020-11-04",38,[258,259],[4400,4415],"Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab",{"trials":4417,"activeCount":98},[],{"trials":4419,"activeCount":98},[],{"trials":4421,"activeCount":98},[],{"trials":4423,"activeCount":98},[],{"intervention":4415,"totalTrials":94,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4434,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4427,"activeCount":98},[],{"trials":4429,"activeCount":98},[4430],{"nctId":4407,"briefTitle":4408,"status":347,"phases":4431,"primaryCompletion":3309,"completion":4410,"start":4411,"enrollment":4412,"conditions":4432,"interventions":4433},[87],[258,259],[4400,4415],{"trials":4435,"activeCount":98},[],{"trials":4437,"activeCount":98},[],{"trials":4439,"activeCount":98},[],{"trials":4441,"activeCount":98},[],{"intervention":4443,"totalTrials":94,"cells":4444},"Imfinzi",{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4446,"activeCount":98},[],{"trials":4448,"activeCount":98},[4449],{"nctId":4450,"briefTitle":4451,"status":497,"phases":4452,"primaryCompletion":4453,"completion":49,"start":179,"enrollment":16,"conditions":4454,"interventions":4456},"NCT06304597","Evaluating PD-1\u002FPD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy",[87],"2025-03-01",[4455],"Locally Advanced Rectal Carcinoma",[4443,4457],"Opdivo",{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[],{"trials":4463,"activeCount":98},[],{"trials":4465,"activeCount":98},[],{"intervention":4457,"totalTrials":94,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4476,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":98},[],{"trials":4471,"activeCount":98},[4472],{"nctId":4450,"briefTitle":4451,"status":497,"phases":4473,"primaryCompletion":4453,"completion":49,"start":179,"enrollment":16,"conditions":4474,"interventions":4475},[87],[4455],[4443,4457],{"trials":4477,"activeCount":98},[],{"trials":4479,"activeCount":98},[],{"trials":4481,"activeCount":98},[],{"trials":4483,"activeCount":98},[],{"intervention":4485,"totalTrials":94,"cells":4486},"Annexin A5",{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4500,"PHASE3":4502,"PHASE4":4504,"NA":4506},{"trials":4488,"activeCount":98},[],{"trials":4490,"activeCount":98},[4491],{"nctId":4492,"briefTitle":4493,"status":497,"phases":4494,"primaryCompletion":4495,"completion":1481,"start":4496,"enrollment":19,"conditions":4497,"interventions":4499},"NCT05133791","NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients",[87],"2024-01-01","2021-09-23",[4498],"Retinal Vein Occlusion",[4485],{"trials":4501,"activeCount":98},[],{"trials":4503,"activeCount":98},[],{"trials":4505,"activeCount":98},[],{"trials":4507,"activeCount":98},[],{"intervention":4509,"totalTrials":94,"cells":4510},"Amikacin Inhalation Dry Powder",{"EARLY_PHASE1":4511,"PHASE1":4513,"PHASE2":4523,"PHASE3":4525,"PHASE4":4527,"NA":4529},{"trials":4512,"activeCount":98},[],{"trials":4514,"activeCount":98},[4515],{"nctId":4516,"briefTitle":4517,"status":497,"phases":4518,"primaryCompletion":3808,"completion":298,"start":4519,"enrollment":3138,"conditions":4520,"interventions":4521},"NCT04249531","Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™",[87],"2020-06-01",[1869],[4509,4522],"Amikacin Injectable Product",{"trials":4524,"activeCount":98},[],{"trials":4526,"activeCount":98},[],{"trials":4528,"activeCount":98},[],{"trials":4530,"activeCount":98},[],{"intervention":4522,"totalTrials":94,"cells":4532},{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4541,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4534,"activeCount":98},[],{"trials":4536,"activeCount":98},[4537],{"nctId":4516,"briefTitle":4517,"status":497,"phases":4538,"primaryCompletion":3808,"completion":298,"start":4519,"enrollment":3138,"conditions":4539,"interventions":4540},[87],[1869],[4509,4522],{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[],{"trials":4548,"activeCount":98},[],{"intervention":4550,"totalTrials":94,"cells":4551},"DCP-001",{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4553,"activeCount":98},[],{"trials":4555,"activeCount":98},[4556],{"nctId":4557,"briefTitle":4558,"status":347,"phases":4559,"primaryCompletion":4560,"completion":4560,"start":4561,"enrollment":2964,"conditions":4562,"interventions":4563},"NCT04739527","Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment",[87],"2025-12-30","2021-06-10",[2302],[4550],{"trials":4565,"activeCount":98},[],{"trials":4567,"activeCount":98},[],{"trials":4569,"activeCount":98},[],{"trials":4571,"activeCount":98},[],{"intervention":4573,"totalTrials":94,"cells":4574},"Indocyanine Green near infrared fluorescence imaging",{"EARLY_PHASE1":4575,"PHASE1":4586,"PHASE2":4588,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4576,"activeCount":98},[4577],{"nctId":4578,"briefTitle":4579,"status":347,"phases":4580,"primaryCompletion":4581,"completion":4581,"start":4582,"enrollment":1508,"conditions":4583,"interventions":4585},"NCT06579430","Diagnostic Accuracy Study of Indocyanine Green for Perfusion Assessment",[86],"2024-05-02","2020-11-05",[4584],"Hypoparathyroidism",[4573,4573],{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"trials":4591,"activeCount":98},[],{"trials":4593,"activeCount":98},[],{"trials":4595,"activeCount":98},[],{"intervention":4597,"totalTrials":94,"cells":4598},"Cyclosporine A dry powder inhalation",{"EARLY_PHASE1":4599,"PHASE1":4610,"PHASE2":4612,"PHASE3":4614,"PHASE4":4616,"NA":4618},{"trials":4600,"activeCount":98},[4601],{"nctId":4602,"briefTitle":4603,"status":497,"phases":4604,"start":4605,"enrollment":612,"conditions":4606,"interventions":4609},"NCT00378677","Dry Powder Inhalation of Cyclosporine A in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome",[86],"2007-02",[4607,4608],"Lung Transplantation","Bronchiolitis Obliterans",[4597],{"trials":4611,"activeCount":98},[],{"trials":4613,"activeCount":98},[],{"trials":4615,"activeCount":98},[],{"trials":4617,"activeCount":98},[],{"trials":4619,"activeCount":98},[],{"intervention":4621,"totalTrials":488,"cells":4622},"Bevacizumab-800CW",{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4647,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4624,"activeCount":98},[],{"trials":4626,"activeCount":98},[4627,4638],{"nctId":4628,"briefTitle":4629,"status":497,"phases":4630,"primaryCompletion":4631,"completion":3129,"start":4632,"enrollment":4633,"conditions":4634,"interventions":4637},"NCT03925285","Image Guided Surgery in Sinonasal Inverted Papilloma",[87],"2021-07-01","2019-05-06",6,[4635,4636],"Inverted Papilloma","Molecular Fluorescence Imaging",[4621],{"nctId":4639,"briefTitle":4640,"status":497,"phases":4641,"primaryCompletion":4642,"completion":4642,"start":4643,"enrollment":30,"conditions":4644,"interventions":4646},"NCT02975219","Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis",[87],"2019-01","2017-05-01",[4645],"Endometriosis",[4621],{"trials":4648,"activeCount":98},[4649,4657],{"nctId":4650,"briefTitle":4651,"status":347,"phases":4652,"primaryCompletion":2982,"completion":4653,"start":1696,"enrollment":4654,"conditions":4655,"interventions":4656},"NCT02583568","Fluorescence Guided Surgery in Breast Cancer",[87,88],"2017-02",26,[18],[4621],{"nctId":4658,"briefTitle":4659,"status":608,"phases":4660,"primaryCompletion":4661,"completion":3041,"start":4662,"enrollment":30,"conditions":4663,"interventions":4666},"NCT02743975","Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma",[87,88],"2018-02-26","2016-12-01",[4664,4665],"Pancreatic Cancer","Pancreatic Adenocarcinoma",[4621],{"trials":4668,"activeCount":98},[],{"trials":4670,"activeCount":98},[],{"trials":4672,"activeCount":98},[4673],{"nctId":4674,"briefTitle":4675,"status":497,"phases":4676,"primaryCompletion":4677,"completion":4453,"start":179,"enrollment":1264,"conditions":4678,"interventions":4681},"NCT06008522","Safety and Feasibility of Immuno-OCT",[91],"2024-09-01",[4679,3061,4680],"Colon Carcinoma","Gastrointestinal Dysplasia",[4621],{"intervention":1658,"totalTrials":1483,"cells":4683},{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4690,"PHASE4":4692,"NA":4698},{"trials":4685,"activeCount":98},[],{"trials":4687,"activeCount":98},[],{"trials":4689,"activeCount":98},[],{"trials":4691,"activeCount":98},[],{"trials":4693,"activeCount":98},[4694],{"nctId":1650,"briefTitle":1651,"status":347,"phases":4695,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":622,"conditions":4696,"interventions":4697},[90],[1656],[1637,1658],{"trials":4699,"activeCount":98},[4700,4709],{"nctId":4701,"briefTitle":4702,"status":497,"phases":4703,"primaryCompletion":2381,"completion":1594,"start":1773,"enrollment":4704,"conditions":4705,"interventions":4707},"NCT01871935","Atropine Effects in Anaesthesia With Sufentanil vs. Remifentanil",[91],70,[4706],"Haemodynamic Fluctuations During Off-pump CABG.",[1658,4708],"Sufentanil",{"nctId":4710,"briefTitle":4711,"status":497,"phases":4712,"primaryCompletion":4453,"completion":4713,"start":3105,"enrollment":4714,"conditions":4715,"interventions":4717},"NCT05757622","Electroencephalogram Based Real-Time Sedation Level Prediction",[],"2025-04-01",1000,[4716],"Procedural Sedation",[4718,1658],"Propofol",{"intervention":4720,"totalTrials":284,"cells":4721},"[18F]MC225",{"EARLY_PHASE1":4722,"PHASE1":4724,"PHASE2":4726,"PHASE3":4738,"PHASE4":4740,"NA":4742},{"trials":4723,"activeCount":98},[],{"trials":4725,"activeCount":98},[],{"trials":4727,"activeCount":98},[4728],{"nctId":4729,"briefTitle":4730,"status":497,"phases":4731,"primaryCompletion":4495,"completion":4495,"start":4732,"enrollment":622,"conditions":4733,"interventions":4737},"NCT05853471","[18F]MC225-PET in Neurodegenerative Disease",[87,88],"2022-02-01",[4734,4735,2649,4736],"Neurodegenerative Diseases","Alzheimer Disease","Mild Cognitive Impairment",[4720],{"trials":4739,"activeCount":98},[],{"trials":4741,"activeCount":98},[],{"trials":4743,"activeCount":98},[4744],{"nctId":4745,"briefTitle":4746,"status":497,"phases":4747,"primaryCompletion":4495,"completion":3081,"start":4410,"enrollment":30,"conditions":4748,"interventions":4750},"NCT05618119","[18F]MC225 PET to Evaluate Gender Differences in BBB P-gp Function",[91],[4749],"Gender",[4720],{"intervention":473,"totalTrials":284,"cells":4752},{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4761,"PHASE3":4763,"PHASE4":4765,"NA":4767},{"trials":4754,"activeCount":98},[],{"trials":4756,"activeCount":98},[4757],{"nctId":2363,"briefTitle":2364,"status":347,"phases":4758,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":1264,"conditions":4759,"interventions":4760},[87],[2369],[2356,2371,2372],{"trials":4762,"activeCount":98},[],{"trials":4764,"activeCount":98},[],{"trials":4766,"activeCount":98},[],{"trials":4768,"activeCount":98},[4769],{"nctId":464,"briefTitle":465,"status":347,"phases":4770,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":4771,"interventions":4772},[],[471],[423,473,474],{"intervention":4774,"totalTrials":284,"cells":4775},"Androgel",{"EARLY_PHASE1":4776,"PHASE1":4778,"PHASE2":4780,"PHASE3":4792,"PHASE4":4794,"NA":4796},{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"trials":4781,"activeCount":98},[4782],{"nctId":4783,"briefTitle":4784,"status":347,"phases":4785,"primaryCompletion":4786,"completion":4786,"start":4787,"enrollment":4788,"conditions":4789,"interventions":4791},"NCT03339635","Short-term Testosterone Replacement in Testicular Cancer Survivors",[88],"2024-06-26","2018-12-21",32,[4790],"Testicular Cancer",[4774],{"trials":4793,"activeCount":98},[],{"trials":4795,"activeCount":98},[],{"trials":4797,"activeCount":98},[4798],{"nctId":4799,"briefTitle":4800,"status":608,"phases":4801,"primaryCompletion":385,"completion":385,"start":4802,"enrollment":488,"conditions":4803,"interventions":4805},"NCT05156606","Testosterone & Tamoxifen Trial",[91],"2022-11-10",[4804],"Male Breast Cancer",[4806],"AndroGel",{"intervention":4057,"totalTrials":284,"cells":4808},{"EARLY_PHASE1":4809,"PHASE1":4811,"PHASE2":4813,"PHASE3":4819,"PHASE4":4821,"NA":4823},{"trials":4810,"activeCount":98},[],{"trials":4812,"activeCount":98},[],{"trials":4814,"activeCount":98},[4815],{"nctId":4050,"briefTitle":4051,"status":347,"phases":4816,"primaryCompletion":2382,"completion":1950,"start":4053,"enrollment":30,"conditions":4817,"interventions":4818},[88],[4055,2386],[4057,4041],{"trials":4820,"activeCount":98},[],{"trials":4822,"activeCount":98},[],{"trials":4824,"activeCount":98},[4825],{"nctId":4826,"briefTitle":4827,"status":497,"phases":4828,"primaryCompletion":2715,"completion":2118,"start":4829,"enrollment":22,"conditions":4830,"interventions":4832},"NCT00691613","Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model",[91],"2010-07",[4831,3287],"Ischemia-Reperfusion Injury",[4057,4833],"NaCl",{"intervention":4835,"totalTrials":284,"cells":4836},"89Zr-bevacizumab",{"EARLY_PHASE1":4837,"PHASE1":4839,"PHASE2":4841,"PHASE3":4843,"PHASE4":4845,"NA":4847},{"trials":4838,"activeCount":98},[],{"trials":4840,"activeCount":98},[],{"trials":4842,"activeCount":98},[],{"trials":4844,"activeCount":98},[],{"trials":4846,"activeCount":98},[],{"trials":4848,"activeCount":98},[4849,4858],{"nctId":4850,"briefTitle":4851,"status":347,"phases":4852,"primaryCompletion":4148,"completion":4148,"start":4853,"enrollment":2973,"conditions":4854,"interventions":4856},"NCT01338090","89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors",[],"2010-04",[4855],"Neuroendocrine Tumors",[4835,4857],"Everolimus",{"nctId":4859,"briefTitle":4860,"status":497,"phases":4861,"primaryCompletion":4339,"start":4862,"enrollment":155,"conditions":4863,"interventions":4864},"NCT01859234","89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma",[91],"2013-05",[527],[4835],{"intervention":1928,"totalTrials":284,"cells":4866},{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4873,"PHASE4":4875,"NA":4881},{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":98},[],{"trials":4872,"activeCount":98},[],{"trials":4874,"activeCount":98},[],{"trials":4876,"activeCount":98},[4877],{"nctId":1911,"briefTitle":1912,"status":347,"phases":4878,"primaryCompletion":1914,"completion":1915,"start":1916,"enrollment":1917,"conditions":4879,"interventions":4880},[90],[1919,1920,1921,1922,1923,1924,1925,1926],[1898,1928],{"trials":4882,"activeCount":98},[4883],{"nctId":4710,"briefTitle":4711,"status":497,"phases":4884,"primaryCompletion":4453,"completion":4713,"start":3105,"enrollment":4714,"conditions":4885,"interventions":4886},[],[4716],[4718,1658],{"intervention":474,"totalTrials":94,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4895,"PHASE4":4897,"NA":4899},{"trials":4890,"activeCount":98},[],{"trials":4892,"activeCount":98},[],{"trials":4894,"activeCount":98},[],{"trials":4896,"activeCount":98},[],{"trials":4898,"activeCount":98},[],{"trials":4900,"activeCount":98},[4901],{"nctId":464,"briefTitle":465,"status":347,"phases":4902,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":4903,"interventions":4904},[],[471],[423,473,474],{"intervention":4906,"totalTrials":94,"cells":4907},"SARS-CoV-2 vaccination",{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4914,"PHASE4":4916,"NA":4918},{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[],{"trials":4913,"activeCount":98},[],{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":98},[4920],{"nctId":4921,"briefTitle":4922,"status":347,"phases":4923,"primaryCompletion":4924,"completion":4925,"start":4926,"enrollment":4927,"conditions":4928,"interventions":4929},"NCT04741386","The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study",[],"2021-06-04","2022-02-25","2021-02-17",854,[2075,182],[4906],{"intervention":4931,"totalTrials":94,"cells":4932},"Group A propofol + remifentanil",{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4937,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4934,"activeCount":98},[],{"trials":4936,"activeCount":98},[],{"trials":4938,"activeCount":98},[],{"trials":4940,"activeCount":98},[],{"trials":4942,"activeCount":98},[],{"trials":4944,"activeCount":98},[4945],{"nctId":4946,"briefTitle":4947,"status":347,"phases":4948,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":1417,"conditions":4951,"interventions":4955},"NCT02067936","Walking the Isobole of Drug Interaction",[91],"2015-09","2014-02",[4952,4953,4954,1656],"Hemodynamic Instability","Disorder of Oxygen Transport","Interaction",[4931,4956,4957,4958],"Group B propofol + remifentanil","Group C propofol + remifentanil","group D propofol + remifentanil",{"intervention":4956,"totalTrials":94,"cells":4960},{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4967,"PHASE4":4969,"NA":4971},{"trials":4962,"activeCount":98},[],{"trials":4964,"activeCount":98},[],{"trials":4966,"activeCount":98},[],{"trials":4968,"activeCount":98},[],{"trials":4970,"activeCount":98},[],{"trials":4972,"activeCount":98},[4973],{"nctId":4946,"briefTitle":4947,"status":347,"phases":4974,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":1417,"conditions":4975,"interventions":4976},[91],[4952,4953,4954,1656],[4931,4956,4957,4958],{"intervention":4957,"totalTrials":94,"cells":4978},{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4983,"PHASE3":4985,"PHASE4":4987,"NA":4989},{"trials":4980,"activeCount":98},[],{"trials":4982,"activeCount":98},[],{"trials":4984,"activeCount":98},[],{"trials":4986,"activeCount":98},[],{"trials":4988,"activeCount":98},[],{"trials":4990,"activeCount":98},[4991],{"nctId":4946,"briefTitle":4947,"status":347,"phases":4992,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":1417,"conditions":4993,"interventions":4994},[91],[4952,4953,4954,1656],[4931,4956,4957,4958],{"intervention":4958,"totalTrials":94,"cells":4996},{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5003,"PHASE4":5005,"NA":5007},{"trials":4998,"activeCount":98},[],{"trials":5000,"activeCount":98},[],{"trials":5002,"activeCount":98},[],{"trials":5004,"activeCount":98},[],{"trials":5006,"activeCount":98},[],{"trials":5008,"activeCount":98},[5009],{"nctId":4946,"briefTitle":4947,"status":347,"phases":5010,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":1417,"conditions":5011,"interventions":5012},[91],[4952,4953,4954,1656],[4931,4956,4957,4958],{"intervention":5014,"totalTrials":94,"cells":5015},"amiodarone",{"EARLY_PHASE1":5016,"PHASE1":5018,"PHASE2":5020,"PHASE3":5022,"PHASE4":5024,"NA":5026},{"trials":5017,"activeCount":98},[],{"trials":5019,"activeCount":98},[],{"trials":5021,"activeCount":98},[],{"trials":5023,"activeCount":98},[],{"trials":5025,"activeCount":98},[],{"trials":5027,"activeCount":98},[5028],{"nctId":5029,"briefTitle":5030,"status":347,"phases":5031,"completion":5032,"start":5033,"enrollment":5034,"conditions":5035,"interventions":5037},"NCT00392431","Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation",[91],"2007-03","2003-01",220,[5036],"Persistant Atrial Fibrillation",[5014],{"intervention":116,"totalTrials":94,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5044,"PHASE3":5046,"PHASE4":5048,"NA":5050},{"trials":5041,"activeCount":98},[],{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"trials":5047,"activeCount":98},[],{"trials":5049,"activeCount":98},[],{"trials":5051,"activeCount":98},[5052],{"nctId":5053,"briefTitle":5054,"status":497,"phases":5055,"primaryCompletion":3081,"completion":5056,"start":3129,"enrollment":5057,"conditions":5058,"interventions":5060},"NCT05140018","Incidence, Course and Outcome of ABMR in Kidney Transplantation",[],"2026-03-01",225,[5059,1954,116],"Antibody-mediated Rejection",[116],{"intervention":5062,"totalTrials":94,"cells":5063},"abciximab",{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5068,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5065,"activeCount":98},[],{"trials":5067,"activeCount":98},[],{"trials":5069,"activeCount":98},[],{"trials":5071,"activeCount":98},[],{"trials":5073,"activeCount":98},[],{"trials":5075,"activeCount":98},[5076],{"nctId":5077,"briefTitle":5078,"status":497,"phases":5079,"primaryCompletion":5080,"completion":1950,"start":524,"enrollment":5081,"conditions":5082,"interventions":5084},"NCT00927615","Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)",[91],"2010-05",534,[5083],"ST-Elevation Myocardial Infarction",[5062,5062],{"intervention":5086,"totalTrials":94,"cells":5087},"Hemoglobin determination + NaCl 0.9% bolus",{"EARLY_PHASE1":5088,"PHASE1":5090,"PHASE2":5092,"PHASE3":5094,"PHASE4":5096,"NA":5098},{"trials":5089,"activeCount":98},[],{"trials":5091,"activeCount":98},[],{"trials":5093,"activeCount":98},[],{"trials":5095,"activeCount":98},[],{"trials":5097,"activeCount":98},[],{"trials":5099,"activeCount":98},[5100],{"nctId":5101,"briefTitle":5102,"status":347,"phases":5103,"primaryCompletion":5104,"completion":5104,"start":5105,"enrollment":622,"conditions":5106,"interventions":5108},"NCT01060683","Non-invasive Measurement of Hemoglobin Concentration With Pulse Co-oximetry",[],"2011-07","2010-01",[5107],"Elective Hepatic Resection",[5086,5109],"hemoglobin determination + Venofundin bolus",{"intervention":5109,"totalTrials":94,"cells":5111},{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5116,"PHASE3":5118,"PHASE4":5120,"NA":5122},{"trials":5113,"activeCount":98},[],{"trials":5115,"activeCount":98},[],{"trials":5117,"activeCount":98},[],{"trials":5119,"activeCount":98},[],{"trials":5121,"activeCount":98},[],{"trials":5123,"activeCount":98},[5124],{"nctId":5101,"briefTitle":5102,"status":347,"phases":5125,"primaryCompletion":5104,"completion":5104,"start":5105,"enrollment":622,"conditions":5126,"interventions":5127},[],[5107],[5086,5109],{"intervention":5129,"totalTrials":94,"cells":5130},"Pemprolizumab",{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5139,"NA":5141},{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"trials":5138,"activeCount":98},[],{"trials":5140,"activeCount":98},[],{"trials":5142,"activeCount":98},[5143],{"nctId":5144,"briefTitle":5145,"status":347,"phases":5146,"primaryCompletion":5147,"completion":5147,"start":1798,"enrollment":5148,"conditions":5149,"interventions":5150},"NCT02600169","Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab",[],"2019-04",150,[21],[5129],{"intervention":5152,"totalTrials":94,"cells":5153},"18F-PSMA-1007",{"EARLY_PHASE1":5154,"PHASE1":5156,"PHASE2":5158,"PHASE3":5160,"PHASE4":5162,"NA":5164},{"trials":5155,"activeCount":98},[],{"trials":5157,"activeCount":98},[],{"trials":5159,"activeCount":98},[],{"trials":5161,"activeCount":98},[],{"trials":5163,"activeCount":98},[],{"trials":5165,"activeCount":98},[5166],{"nctId":5167,"briefTitle":5168,"status":347,"phases":5169,"primaryCompletion":5170,"completion":5170,"start":5171,"enrollment":3138,"conditions":5172,"interventions":5177},"NCT05534594","Evaluation of the 18F-PSMA Positron Emission Tomography (PET)\u002FCT in Patients With Medullary Thyroid Cancer",[91],"2024-12-31","2022-08-19",[5173,5174,5175,5176],"Medullary Thyroid Cancer","Medullary Thyroid Carcinoma","Thyroid Carcinoma, Medullary","Thyroid Cancer, Medullary",[5152],{"intervention":5179,"totalTrials":94,"cells":5180},"Antidepressant",{"EARLY_PHASE1":5181,"PHASE1":5183,"PHASE2":5185,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5182,"activeCount":98},[],{"trials":5184,"activeCount":98},[],{"trials":5186,"activeCount":98},[],{"trials":5188,"activeCount":98},[],{"trials":5190,"activeCount":98},[],{"trials":5192,"activeCount":98},[5193],{"nctId":5194,"briefTitle":5195,"status":497,"phases":5196,"primaryCompletion":5197,"completion":5197,"start":1891,"enrollment":5198,"conditions":5199,"interventions":5201},"NCT02934035","Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder",[],"2017-09",10000,[5200],"Major Depressive Disorder",[5179],{"intervention":5203,"totalTrials":94,"cells":5204},"Ganciclovir",{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5209,"PHASE3":5211,"PHASE4":5213,"NA":5215},{"trials":5206,"activeCount":98},[],{"trials":5208,"activeCount":98},[],{"trials":5210,"activeCount":98},[],{"trials":5212,"activeCount":98},[],{"trials":5214,"activeCount":98},[],{"trials":5216,"activeCount":98},[5217],{"nctId":5218,"briefTitle":5219,"status":497,"phases":5220,"primaryCompletion":5221,"completion":4368,"start":5222,"enrollment":779,"conditions":5223,"interventions":5225},"NCT03698435","(Val)Ganciclovir TDM in Transplant Recipients",[],"2019-11-30","2018-05-25",[5224],"Cytomegalovirus Infections",[5203,5226],"Valganciclovir",{"intervention":5226,"totalTrials":94,"cells":5228},{"EARLY_PHASE1":5229,"PHASE1":5231,"PHASE2":5233,"PHASE3":5235,"PHASE4":5237,"NA":5239},{"trials":5230,"activeCount":98},[],{"trials":5232,"activeCount":98},[],{"trials":5234,"activeCount":98},[],{"trials":5236,"activeCount":98},[],{"trials":5238,"activeCount":98},[],{"trials":5240,"activeCount":98},[5241],{"nctId":5218,"briefTitle":5219,"status":497,"phases":5242,"primaryCompletion":5221,"completion":4368,"start":5222,"enrollment":779,"conditions":5243,"interventions":5244},[],[5224],[5203,5226],{"intervention":5246,"totalTrials":94,"cells":5247},"Atropine",{"EARLY_PHASE1":5248,"PHASE1":5250,"PHASE2":5252,"PHASE3":5254,"PHASE4":5256,"NA":5258},{"trials":5249,"activeCount":98},[],{"trials":5251,"activeCount":98},[],{"trials":5253,"activeCount":98},[],{"trials":5255,"activeCount":98},[],{"trials":5257,"activeCount":98},[],{"trials":5259,"activeCount":98},[5260],{"nctId":5261,"briefTitle":5262,"status":347,"phases":5263,"primaryCompletion":1773,"completion":1773,"start":2167,"enrollment":539,"conditions":5264,"interventions":5266},"NCT01871922","Atropine-effect During Propofol\u002FRemifentanil Induction",[91],[5265],"Anesthesia-induced Negative Hemodynamic Effects",[5246],{"intervention":4833,"totalTrials":94,"cells":5268},{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5277,"NA":5279},{"trials":5270,"activeCount":98},[],{"trials":5272,"activeCount":98},[],{"trials":5274,"activeCount":98},[],{"trials":5276,"activeCount":98},[],{"trials":5278,"activeCount":98},[],{"trials":5280,"activeCount":98},[5281],{"nctId":4826,"briefTitle":4827,"status":497,"phases":5282,"primaryCompletion":2715,"completion":2118,"start":4829,"enrollment":22,"conditions":5283,"interventions":5284},[91],[4831,3287],[4057,4833],{"intervention":4857,"totalTrials":94,"cells":5286},{"EARLY_PHASE1":5287,"PHASE1":5289,"PHASE2":5291,"PHASE3":5293,"PHASE4":5295,"NA":5297},{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[],{"trials":5292,"activeCount":98},[],{"trials":5294,"activeCount":98},[],{"trials":5296,"activeCount":98},[],{"trials":5298,"activeCount":98},[5299],{"nctId":4850,"briefTitle":4851,"status":347,"phases":5300,"primaryCompletion":4148,"completion":4148,"start":4853,"enrollment":2973,"conditions":5301,"interventions":5302},[],[4855],[4835,4857],{"intervention":4708,"totalTrials":94,"cells":5304},{"EARLY_PHASE1":5305,"PHASE1":5307,"PHASE2":5309,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5306,"activeCount":98},[],{"trials":5308,"activeCount":98},[],{"trials":5310,"activeCount":98},[],{"trials":5312,"activeCount":98},[],{"trials":5314,"activeCount":98},[],{"trials":5316,"activeCount":98},[5317],{"nctId":4701,"briefTitle":4702,"status":497,"phases":5318,"primaryCompletion":2381,"completion":1594,"start":1773,"enrollment":4704,"conditions":5319,"interventions":5320},[91],[4706],[1658,4708],{"intervention":5322,"totalTrials":94,"cells":5323},"Liquid nitrogen",{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5330,"PHASE4":5332,"NA":5334},{"trials":5325,"activeCount":98},[],{"trials":5327,"activeCount":98},[],{"trials":5329,"activeCount":98},[],{"trials":5331,"activeCount":98},[],{"trials":5333,"activeCount":98},[],{"trials":5335,"activeCount":98},[5336],{"nctId":5337,"briefTitle":5338,"status":347,"phases":5339,"primaryCompletion":3209,"completion":3209,"start":2981,"enrollment":155,"conditions":5340,"interventions":5342},"NCT02572557","TruFreeze Cryotherapy Central Airway Disease",[91],[5341],"Airway Obstruction",[5322],{"intervention":5344,"totalTrials":94,"cells":5345},"propofol + remifentanil 0 ng\u002Fml",{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5347,"activeCount":98},[],{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[],{"trials":5353,"activeCount":98},[],{"trials":5355,"activeCount":98},[],{"trials":5357,"activeCount":98},[5358],{"nctId":5359,"briefTitle":5360,"status":347,"phases":5361,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5365,"interventions":5367},"NCT01053611","Composite Variability Index Versus Bispectral Index (BIS)",[91],"2010-09","2009-09",140,[5366],"Sedation During",[5344,5368,5369,5370,5344,5368,5370,5370,5344,5368,5369,5370],"propofol + remifentanil 2 ng\u002Fml","propofol + remifentanil 4 ng\u002Fml","propofol + remifentanil 6 ng\u002Fml",{"intervention":5368,"totalTrials":94,"cells":5372},{"EARLY_PHASE1":5373,"PHASE1":5375,"PHASE2":5377,"PHASE3":5379,"PHASE4":5381,"NA":5383},{"trials":5374,"activeCount":98},[],{"trials":5376,"activeCount":98},[],{"trials":5378,"activeCount":98},[],{"trials":5380,"activeCount":98},[],{"trials":5382,"activeCount":98},[],{"trials":5384,"activeCount":98},[5385],{"nctId":5359,"briefTitle":5360,"status":347,"phases":5386,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5387,"interventions":5388},[91],[5366],[5344,5368,5369,5370,5344,5368,5370,5370,5344,5368,5369,5370],{"intervention":5369,"totalTrials":94,"cells":5390},{"EARLY_PHASE1":5391,"PHASE1":5393,"PHASE2":5395,"PHASE3":5397,"PHASE4":5399,"NA":5401},{"trials":5392,"activeCount":98},[],{"trials":5394,"activeCount":98},[],{"trials":5396,"activeCount":98},[],{"trials":5398,"activeCount":98},[],{"trials":5400,"activeCount":98},[],{"trials":5402,"activeCount":98},[5403],{"nctId":5359,"briefTitle":5360,"status":347,"phases":5404,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5405,"interventions":5406},[91],[5366],[5344,5368,5369,5370,5344,5368,5370,5370,5344,5368,5369,5370],{"intervention":5370,"totalTrials":94,"cells":5408},{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5413,"PHASE3":5415,"PHASE4":5417,"NA":5419},{"trials":5410,"activeCount":98},[],{"trials":5412,"activeCount":98},[],{"trials":5414,"activeCount":98},[],{"trials":5416,"activeCount":98},[],{"trials":5418,"activeCount":98},[],{"trials":5420,"activeCount":98},[5421],{"nctId":5359,"briefTitle":5360,"status":347,"phases":5422,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5423,"interventions":5424},[91],[5366],[5344,5368,5369,5370,5344,5368,5370,5370,5344,5368,5369,5370],{"intervention":5426,"totalTrials":94,"cells":5427},"89Zr-Pembrolizumab",{"EARLY_PHASE1":5428,"PHASE1":5430,"PHASE2":5432,"PHASE3":5434,"PHASE4":5436,"NA":5438},{"trials":5429,"activeCount":98},[],{"trials":5431,"activeCount":98},[],{"trials":5433,"activeCount":98},[],{"trials":5435,"activeCount":98},[],{"trials":5437,"activeCount":98},[],{"trials":5439,"activeCount":98},[5440],{"nctId":5441,"briefTitle":5442,"status":347,"phases":5443,"primaryCompletion":5444,"completion":5445,"start":5446,"enrollment":16,"conditions":5447,"interventions":5449},"NCT02760225","Pembrolizumab-PET Imaging",[91],"2019-03","2020-09","2016-10-24",[21,5448],"Non-small Cell Lung Cancer",[5426],{"intervention":5451,"totalTrials":94,"cells":5452},"posaconazole",{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5457,"PHASE3":5459,"PHASE4":5461,"NA":5463},{"trials":5454,"activeCount":98},[],{"trials":5456,"activeCount":98},[],{"trials":5458,"activeCount":98},[],{"trials":5460,"activeCount":98},[],{"trials":5462,"activeCount":98},[],{"trials":5464,"activeCount":98},[5465],{"nctId":5466,"briefTitle":5467,"status":347,"phases":5468,"primaryCompletion":5469,"completion":5470,"start":5471,"enrollment":5472,"conditions":5473,"interventions":5475},"NCT02492802","Effect of Inflammation on Pharmacokinetics of Posaconazole",[],"2017-06-01","2017-08-01","2015-08-13",64,[5474],"Mycoses",[5451],{"intervention":5477,"totalTrials":94,"cells":5478},"phenylephrine",{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5480,"activeCount":98},[],{"trials":5482,"activeCount":98},[],{"trials":5484,"activeCount":98},[],{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[],{"trials":5490,"activeCount":98},[5491],{"nctId":5492,"briefTitle":5493,"status":347,"phases":5494,"primaryCompletion":2535,"completion":2784,"start":2119,"enrollment":539,"conditions":5495,"interventions":5497},"NCT01609491","Phenylephrine Versus Norepinephrine in Ophthalmic Surgery",[91],[5496],"Bloodpressure",[5477,5498],"norepinephrine",{"intervention":5498,"totalTrials":94,"cells":5500},{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5505,"PHASE3":5507,"PHASE4":5509,"NA":5511},{"trials":5502,"activeCount":98},[],{"trials":5504,"activeCount":98},[],{"trials":5506,"activeCount":98},[],{"trials":5508,"activeCount":98},[],{"trials":5510,"activeCount":98},[],{"trials":5512,"activeCount":98},[5513],{"nctId":5492,"briefTitle":5493,"status":347,"phases":5514,"primaryCompletion":2535,"completion":2784,"start":2119,"enrollment":539,"conditions":5515,"interventions":5516},[91],[5496],[5477,5498],{"intervention":5518,"totalTrials":94,"cells":5519},"orlistat",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5530},{"trials":5521,"activeCount":98},[],{"trials":5523,"activeCount":98},[],{"trials":5525,"activeCount":98},[],{"trials":5527,"activeCount":98},[],{"trials":5529,"activeCount":98},[],{"trials":5531,"activeCount":98},[5532],{"nctId":5533,"briefTitle":5534,"status":347,"phases":5535,"completion":5536,"start":5537,"enrollment":19,"conditions":5538,"interventions":5540},"NCT00461799","Orlistat Treatment of Crigler-Najjar Disease",[91],"2004-01","2003-09",[5539],"Crigler-Najjar Syndrome",[5518],{"intervention":5542,"totalTrials":94,"cells":5543},"procedure:sevoflurane-remifentanil\u002Fsufentanil",{"EARLY_PHASE1":5544,"PHASE1":5546,"PHASE2":5548,"PHASE3":5550,"PHASE4":5552,"NA":5554},{"trials":5545,"activeCount":98},[],{"trials":5547,"activeCount":98},[],{"trials":5549,"activeCount":98},[],{"trials":5551,"activeCount":98},[],{"trials":5553,"activeCount":98},[],{"trials":5555,"activeCount":98},[5556],{"nctId":5557,"briefTitle":5558,"status":347,"phases":5559,"primaryCompletion":2167,"completion":2167,"start":5362,"enrollment":673,"conditions":5560,"interventions":5562},"NCT01248871","\"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail",[91],[5561],"Kidney Donation\u002FTransplantation",[5542,5563,5564],"volatile agent only during reperfusion","propofol-remifentanil\u002Fsufentanil",{"intervention":5563,"totalTrials":94,"cells":5566},{"EARLY_PHASE1":5567,"PHASE1":5569,"PHASE2":5571,"PHASE3":5573,"PHASE4":5575,"NA":5577},{"trials":5568,"activeCount":98},[],{"trials":5570,"activeCount":98},[],{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":98},[],{"trials":5578,"activeCount":98},[5579],{"nctId":5557,"briefTitle":5558,"status":347,"phases":5580,"primaryCompletion":2167,"completion":2167,"start":5362,"enrollment":673,"conditions":5581,"interventions":5582},[91],[5561],[5542,5563,5564],{"intervention":5564,"totalTrials":94,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5589,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5586,"activeCount":98},[],{"trials":5588,"activeCount":98},[],{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[],{"trials":5594,"activeCount":98},[],{"trials":5596,"activeCount":98},[5597],{"nctId":5557,"briefTitle":5558,"status":347,"phases":5598,"primaryCompletion":2167,"completion":2167,"start":5362,"enrollment":673,"conditions":5599,"interventions":5600},[91],[5561],[5542,5563,5564],{"intervention":5602,"totalTrials":94,"cells":5603},"mRNA-1273 SARS-CoV-2 vaccine from Moderna",{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5608,"PHASE3":5610,"PHASE4":5612,"NA":5614},{"trials":5605,"activeCount":98},[],{"trials":5607,"activeCount":98},[],{"trials":5609,"activeCount":98},[],{"trials":5611,"activeCount":98},[],{"trials":5613,"activeCount":98},[],{"trials":5615,"activeCount":98},[5616],{"nctId":5617,"briefTitle":5618,"status":497,"phases":5619,"primaryCompletion":4924,"completion":5620,"start":5621,"enrollment":5622,"conditions":5623,"interventions":5624},"NCT04715438","Vaccination Against COVID-19 in Cancer",[91],"2025-04","2021-01-08",791,[32],[5602],{"intervention":5626,"totalTrials":94,"cells":5627},"Cefazolin",{"EARLY_PHASE1":5628,"PHASE1":5630,"PHASE2":5632,"PHASE3":5634,"PHASE4":5636,"NA":5638},{"trials":5629,"activeCount":98},[],{"trials":5631,"activeCount":98},[],{"trials":5633,"activeCount":98},[],{"trials":5635,"activeCount":98},[],{"trials":5637,"activeCount":98},[],{"trials":5639,"activeCount":98},[5640],{"nctId":5641,"briefTitle":5642,"status":347,"phases":5643,"primaryCompletion":3309,"completion":3105,"start":5644,"enrollment":5645,"conditions":5646,"interventions":5650},"NCT06030713","Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome",[91],"2019-03-01",33,[5647,5648,5649],"Microbial Colonization","Antibiotic Side Effect","Cesarean Section Complications",[5626],{"intervention":5652,"totalTrials":94,"cells":5653},"screening, prevention and counselling",{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5658,"PHASE3":5660,"PHASE4":5662,"NA":5664},{"trials":5655,"activeCount":98},[],{"trials":5657,"activeCount":98},[],{"trials":5659,"activeCount":98},[],{"trials":5661,"activeCount":98},[],{"trials":5663,"activeCount":98},[],{"trials":5665,"activeCount":98},[5666],{"nctId":5667,"briefTitle":5668,"status":347,"phases":5669,"primaryCompletion":5670,"completion":5670,"start":5671,"enrollment":5672,"conditions":5673,"interventions":5674},"NCT05239572","Scaling Up NCD Interventions in South East Asia",[91],"2023-06-30","2022-03-31",16850,[353,184,781],[5652],{"intervention":5676,"totalTrials":94,"cells":5677},"Iohexol",{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5682,"PHASE3":5684,"PHASE4":5686,"NA":5688},{"trials":5679,"activeCount":98},[],{"trials":5681,"activeCount":98},[],{"trials":5683,"activeCount":98},[],{"trials":5685,"activeCount":98},[],{"trials":5687,"activeCount":98},[],{"trials":5689,"activeCount":98},[5690],{"nctId":5691,"briefTitle":5692,"status":497,"phases":5693,"primaryCompletion":1116,"completion":1116,"start":5694,"enrollment":5695,"conditions":5696,"interventions":5699},"NCT06259422","Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate",[91],"2024-06-01",208,[5697,5698,182],"Kidney Function Issue","Diagnosis",[5676]]